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EXECUTIVE SUMMARY 
 
 
As of January 2006, 42 million elderly and disabled people on Medicare have access to 
private plans that offer the new Medicare prescription drug benefit.  Across the 50 states, 
there are a total of 1,429 stand-alone prescription drug plans (PDPs), in addition to 1,314 
Medicare Advantage plans, that provide the new drug benefit.  Coverage offered by these 
Medicare prescription drug plans must meet minimum federal standards.  For example, 
plans are required to provide a standard drug benefit or one that is actuarially equivalent.  
At the same time, plans have flexibility to modify the standard drug benefit design and 
establish their own formularies, and also can offer enhanced benefit packages, subject to 
review and approval.  The concept behind this choice-based approach is that Medicare 
beneficiaries, primarily seniors but also people with disabilities, will choose among 
competing drug plans to select the plan that is most likely to meet their individual needs.   
 
With the proliferation of Medicare drug plans in 2006, the key questions for beneficiaries 
include which plans cover the specific drugs they take and how much they will pay out-of-
pocket for these medications.  The Centers for Medicare and Medicaid Services (CMS), the 
agency responsible for administering the new drug benefit, has created a number of tools to 
help beneficiaries compare key features of the plans available in their area, such as 
formularies, costs, and the use of utilization management tools.   
 
This report examines the extent to which the new stand-alone prescription drug plans vary 
with respect to key features that are likely to be important to Medicare beneficiaries’ access 
to medications and out-of-pocket costs.  The study takes a detailed look at the drug 
coverage offered by 14 national and near-national organizations that account for a total of 
1,222 of the 1,429 stand-alone drug plans available to beneficiaries nationwide.  It looks at 
a sample of 152 generic and brand-name drugs, selected to include drugs commonly used 
by Medicare beneficiaries, such as those treating high cholesterol and high blood pressure, 
as well as some less common, high-cost drugs used to treat specific conditions such as 
osteoporosis and rheumatoid arthritis.    
 
The study finds significant variation across plans with respect to formularies, cost sharing in 
the initial benefit period, and the application of utilization management tools.  These 
differences could have significant implications for beneficiaries in terms of access to needed 
medications and out-of-pocket costs.  They also underscore both the importance to 
beneficiaries of making good choices when selecting among competing Medicare prescription 
drug plans, and the challenges in choosing wisely when so many plan features vary. 
 
 
KEY FINDINGS 
 
Formularies.   All of the Medicare drug plans examined in this study use formularies to 
help manage drug utilization and costs, but the list of covered drugs differs across plans.   
These differences could have a substantial impact on enrollees with a preference, or current 
prescription, for one particular medication, in terms of out-of-pocket spending – unless they 
ask their physician to switch them to a drug that is on the plan’s formulary.  
 
• None of the 35 drug plans cover all 152 of the drugs in the sample.  On average, the 
plans cover 81 percent of those drugs, ranging from 64 percent in the most 
restrictive formulary to 97 percent in the least restrictive. 
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• While all of the top 10 most commonly prescribed generic drugs are covered by 32 of 
the 35 plans, only 18 of the 35 plans cover all top 10 brand-name drugs. Among the 
top 10 drugs, the most frequently omitted – in favor of therapeutically similar 
alternatives – include Nexium, Diovan, and Plavix. 
 
• Formulary comprehensiveness varies considerably by drug group.  Averaged across 
all plans in the study, about 90 percent of antidepressants, beta blockers, and tumor 
necrosis factor inhibitors (used to treat rheumatoid arthritis) are covered on plan 
formularies, while only about 60 percent of hormonal agents (used to treat 
osteoporosis) and proton pump inhibitors (used to treat gastrointestinal problems) 
are covered. 
 
Cost Sharing and Tiering Structure.  The amount enrollees pay for covered drugs varies 
substantially across plans, due to variation in placement of covered drugs on separate cost-
sharing tiers (e.g., tiers for generic vs. brand-name drugs, preferred vs. non-preferred 
drugs, or “specialty” drugs) and the amount plans charge for covered drugs based on their 
cost-sharing design for each tier.   
 
• The amount enrollees pay for a given drug when it is covered on the plan’s formulary 
varies considerably across plans.  An enrollee could pay from $15 to $62 for Norvasc 
(for high blood pressure), $15 to $66 for Fosamax (for osteoporosis), and $15 to 
$100 for Namenda (for Alzheimer’s).  An even more dramatic example of this 
variation across plans is for Enbrel (for rheumatoid arthritis), with cost sharing that 
varies from a low of $20 in one Medicare drug plan to $1,276 in a plan that covers 
the drug but charges enrollees 75 percent of its cost.   
 
• The most common cost-sharing arrangement is a three-tier system of copayments.  
Among the 21 plans with such arrangements, the median cost-sharing is $5 for first-
tier drugs, $25 for second-tier drugs, and $53 for third-tier drugs.   
 
• Most of the 35 plans also use a “specialty tier,” primarily for relatively high-cost 
biotechnology or injectable drugs.  Although CMS issued guidance encouraging plans 
not to charge beneficiaries more than 25 percent of the cost of these drugs, eight 
plans charge between 30 percent and 33 percent.  For the specialty tier drugs in the 
study’s sample, beneficiaries would be required to pay between $149 and $450 for a 
one-month supply in plans that cover these drugs. 
 
• There is relatively modest variation across plans – much less variation than other 
parameters in this analysis – in the negotiated price that enrollees pay for covered 
drugs when they are required to pay 100 percent of the cost (in the deductible and 
the coverage gap, or so-called “doughnut hole”).  
   
Utilization Management Tools.  Utilization management tools – prior authorization, 
quantity limits, and step therapy – are used by plans to help manage drug use and total 
costs.  The application of such tools can be an important way for plans to steer beneficiaries 
to specific drugs as well as to control the use of certain drugs.  Yet enrollees may not know 
whether these tools might create a real barrier to getting their medications until they first 
attempt to fill a prescription for a specific drug under their plan. 
   
• Plans vary significantly in the type of utilization management tools they use to 
restrict enrollees’ access to specific drugs, and in the frequency these tools are 
applied.  Four of the 35 plans use these tools on fewer than one in 10 of their 
covered drugs, while 13 plans do so on at least one in four covered drugs.   
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• Plans are more likely to apply quantity limits for covered drugs than to require step 
therapy, which is applied slightly more often than prior authorization requirements.  
 
• At least half of the plans use one or more utilization management tools on five of the 
top 10 brand-name drugs, most often quantity limits.  Restrictions are far less 
commonly used for the top 10 generic drugs. 
 
 
DISCUSSION 
 
This study confirms considerable variation across plans with respect to virtually every key 
indicator, including the comprehensiveness of formularies, the treatment of covered drugs 
as preferred or non-preferred, the amount enrollees pay for covered drugs, and the 
application of utilization management tools.  These differences reflect decisions made by the 
organizations that sponsor Medicare drug plans to encourage enrollees’ use of generic drugs 
in lieu of comparable brand-name drugs, and the use of preferred over non-preferred 
brands.  It is beyond the scope of this paper to assess whether or not these decisions are 
appropriate, but the findings underscore the importance for beneficiaries in making careful 
decisions when choosing among the many Medicare drug plans available to them.   
 
Variation across Medicare drug plans could have a significant impact on beneficiaries’ access 
to needed medications and their out-of-pocket expenditures over the course of a year.  The 
potential impact of these variations is heightened by the fact that once beneficiaries enroll 
in a plan, they are generally locked into that choice for the remainder of the year.  Without 
careful consideration of the ways in which plans differ, beneficiaries may find themselves 
paying hundreds, if not thousands, of dollars more to fill their prescriptions, depending upon 
the plan they select.  For several commonly used brand-name drugs, enrollees could face a 
four-fold difference in cost sharing for a 30-day supply from one plan to another, even when 
the drug is covered by both plans and filled at a network pharmacy.  The absence of any 
standardization for many features of drug plan benefit design, and even some of the basic 
terminology used to describe these plans, is likely to make apples-to-apples comparisons 
across plans more difficult for consumers. 
 
Given the significant needs and vulnerabilities of the Medicare population, the findings of 
this study confirm the need for careful oversight to monitor plan compliance and minimize 
unnecessary complexity in the Medicare prescription drug plan marketplace.  Such oversight 
is critical to secure protections for beneficiaries who are unable to compare key features of 
Medicare drug plans or to predict their future medication needs. 
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INTRODUCTION 
 
 
The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) 
established a new voluntary prescription drug benefit for people on Medicare, known as Part 
D.  The benefit, which took effect in January 2006, is available to beneficiaries who are 
enrolled in private plans that have been approved by the federal government to offer 
Medicare’s new drug coverage.  In most parts of the country, beneficiaries have a choice of 
at least 40 stand-alone prescription drug plans (PDPs) that offer coverage for prescription 
drugs only.  Across the 34 regions established for Part D (excluding the territories), there 
are a total of 1,429 stand-alone drug plans available.  Most beneficiaries can also choose to 
get drug coverage from Medicare Advantage plans that offer the drug benefit in addition to 
other Medicare benefits.   
 
The MMA requires organizations offering drug plans to provide a standard benefit which is 
defined in the law1, but gives them flexibility to modify the benefit, establish formularies 
and cost-sharing amounts, and apply utilization management tools to covered drugs, such 
as prior authorization, quantity limits, and step therapy.2  Plan designs are subject to the 
approval of the Centers for Medicare and Medicaid Services (CMS), the agency that 
administers the Medicare program.  From a beneficiary perspective, the formulary, or list of 
covered drugs, is among the most important features of a Medicare drug plan.  Another key 
concern for beneficiaries is how much they will pay at the pharmacy when they fill their 
prescriptions.  Beneficiaries can evaluate these features of the Medicare drug plans available 
in their region to select one that is most likely to meet their individual needs. 
 
CMS requires that organizations offering drug plans meet minimum standards to ensure that 
plan formularies cover a full range of medications needed by beneficiaries and are not 
designed to discriminate against certain types of beneficiaries or discourage their 
enrollment.  Formulary guidelines issued by CMS in 2005 were based on a therapeutic 
classification scheme developed specifically for Medicare drug plans by the United States 
Pharmacopoeia (USP).  These guidelines require a minimum number of drugs to be covered 
in each class and key drug type of the USP classification system, and coverage of all or 
substantially all drugs in six specified classes (anticonvulsants, antidepressants, 
antineoplastics, antipsychotics, antiretrovirals, and immune suppressants).  At the same 
time, CMS gives organizations latitude to modify their formularies, subject to review and 
approval.   
 
CMS allowed each approved sponsor organization to offer up to three unique plan options in 
2006 which could vary in benefit design, formulary, and utilization management tools.  At 
least one plan offered by each organization must be actuarially equivalent to the standard 
benefit.  Data released by CMS in the fall of 2005 provided basic information about these 
plans, including monthly premiums, deductible and cost-sharing amounts, and which drugs 
are covered on their formularies.  At a basic level, the Medicare drug plans appear to be 
                                                 
1 The standard benefit defined in the MMA has a $250 deductible and 25 percent beneficiary coinsurance in the 
initial benefit period.  The initial benefit period ends after $2,250 in total drug spending.  From this point until 
catastrophic coverage begins (after a beneficiary incurs $3,600 in out-of-pocket drug costs, which corresponds to 
$5,100 in total drug costs under the standard benefit), the beneficiary pays 100 percent of drug costs; this gap in 
coverage is commonly referred to as the “doughnut hole.”  Organizations must either offer at least one plan with 
the standard benefit design or a plan design that is actuarially equivalent to this benefit. 
2 Plans can require the enrollee to show that a particular drug is medically necessary before granting permission to 
fill the prescription; limit the quantity of drugs that they cover over a certain period of time, such as limiting 
prescriptions to a certain number of pills each time the prescription is filled; and restrict coverage of a particular 
drug unless and until certain other drug therapies have been tried first. 
 2
similar to each other in many respects.  Most plans do not replicate the standard benefit, 
but instead offer one that is actuarially equivalent.  Most plans do not have a deductible or 
charge a flat 25 percent coinsurance rate.  Most plans do have a gap in coverage, known as 
the “doughnut hole.”  And all of the stand-alone drug plans cover a majority of the top 100 
drugs commonly used by Medicare beneficiaries, according to CMS.  
 
Underlying these similarities, however, this report shows there is a great deal of variation in 
Medicare’s new prescription drug plans.  Specifically, this study takes a more detailed look 
at the drug coverage offered by the stand-alone prescription drug plans offered by 14 
national and near-national organizations that sponsor PDPs, focusing on three key areas: 
 
1. Formularies.  How comprehensive are the Medicare drug plan formularies?  To what 
extent do plans vary with respect to the specific drugs that they cover and the 
placement of drugs on preferred versus non-preferred tiers?   
 
2. Cost Sharing.  How much variation is there across plans in the amount enrollees 
pay for their medications during the initial coverage period and in the coverage gap 
(the so-called “doughnut hole”)?     
 
3. Utilization Management Tools.  To what degree do plans apply utilization 
management practices that affect access to certain drugs, and to what extent does 
the application of these tools vary across plans?   
 
Variations in these three areas could have significant implications for enrollees in terms of 
out-of-pocket drug spending and access to needed medications.  The potential impact of 
these variations is heightened by the fact that once beneficiaries enroll in a specific plan, 
they are generally locked into their chosen plan for the remainder of the year. 
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METHODS3 
 
 
Overview of Medicare Drug Plans in This Analysis 
 
Our analysis focuses on stand-alone prescription drug plans (PDPs) offered by the 14 
national and near-national organizations that sponsor such plans in at least 31 of the 34 
regions established by CMS (excluding the territories).  (See Appendix Table A1)  These 14 
organizations each offer between one and four different plan designs for a total of 35 unique 
plan options.  Typically the organizations establish a different benefit structure for each of 
the plan options, and some also offer a different formulary for one of their plan options.   
 
Across the 34 regions throughout the country, the 14 organizations that sponsor stand-
alone PDPs account for 1,222 plans – 86 percent of the 1,429 PDPs offered nationwide.4  
Our analysis excludes the remaining 14 percent of plans – mainly local plans offered in a 
single region or a smaller number of regions – due to limitations imposed by collecting drug 
coverage and price data from the CMS website.  We do not examine prescription drug 
benefits offered by Medicare 
Advantage prescription drug (MA-PD) 
plans, for similar reasons.   
 
Organizations’ benefit designs and 
formularies are normally unchanged 
across the regions, although some 
exceptions exist.  For example, 
several organizations modify cost-
sharing levels by a few dollars or a 
few percentage points from region to 
region, presumably to maintain 
compliance with actuarial equivalence 
requirements.  For simplicity, we 
present our findings in terms of the 
35 unique plan options offered by 
these 14 organizations that are 
available across the country, rather 
than counting each of these plan 
options separately for all of the 
regions in which they are offered. 
 
Benefit Design 
 
The characteristics of the 35 plans 
that we analyzed, representing 86 
percent of all PDPs nationwide, are 
similar to the universe of stand-alone 
prescription drug plans in terms of 
average premiums and benefit 
design.  (See Table 1)  The average 
2006 unweighted premium among the 
                                                 
3 See Appendix A for a more detailed description of the study methodology. 
4 The 10 national organizations offer 882 (62 percent) of the 1,429 plans offered nationwide, and the four near-
national firms offer another 340 plans (24 percent) nationwide.   
National/
Near-National 
Plans All Plans 
Number of plans 1,222 1,429
Benefit design
Standard 5.2% 9.2%
Actuarially equivalent 49.2% 48.2%
Enhanced 45.7% 42.5%
Average premium1 $38.14 $37.43
Deductible amount
$250.00 29.6% 33.8%
Partial (less than $250) 8.2% 7.8%
No deductible 62.2% 58.4%
Uses tiered cost sharing 94.8% 90.8%
Coverage in the gap2
No gap coverage 83.6% 84.6%
Generic coverage only 13.8% 13.1%
Brand and generic coverage 2.5% 2.3%
Initial coverage limit
Standard ($2,250 in total drug costs) 87.3% 87.8%
Lower coverage limit 10.1% 9.5%
No coverage limit 2.5% 2.3%
SOURCE: CMS landscape file (11-15-05).  Statistics for national plans are based 
on all regional offerings of each plans and thus differ slightly for other results 
presented in the report.
NOTE:  Territories are excluded from all calculations. 
1: The Administration's FY 2007 Budget assumes a Part D premium of $25 per 
month for 2006. The Administration's estimate is lower than the average 
reported in this table because it (a) reflects CMS estimates of expected higher 
enrollment in low-premium plans, (b) includes only the portion of the premium 
for enhanced plans that corresponds to the basic benefit, and (c) includes 
premiums for Medicare Advantage plans.
2: The coverage gap (or "doughnut hole") is from the end of the initial benefit 
period up to $3,600 in out-of-pocket payments.
Table 1: Comparison of National and Near-National Plans 
in This Analysis to All Plans Available Nationwide
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plans analyzed for this study is $38.14, compared with $37.43 for the universe of PDPs 
nationwide. Only a small share of the PDPs in our sample (5%) and nationwide (9%) offer 
the standard drug benefit as defined in the MMA, but nearly half of our sample plans and 
the national plans offer a drug benefit that is actuarially equivalent to the standard.  Close 
to half of the PDPs in our sample (46%) and nationwide (43%) offer an enhanced benefit 
package.  Roughly six in 10 PDPs in our sample (62%) and nationwide (58%) do not have a 
deductible.  More than eight in 10 PDPs in our sample (84%) and nationwide (85%) have a 
coverage gap (the so-called “doughnut hole”) and only a very small share of the plans that 
we studied (2.5%) and all PDPs nationwide (2.3%) provide coverage of both brand-name 
and generic drugs in the gap. 
 
Sample of Drugs in this Analysis 
 
To analyze plan formularies and cost-sharing arrangements, we examined coverage of a 
pre-selected sample of 152 drugs that together represent nearly 60 percent of the total 
prescription drug volume for Medicare beneficiaries, as reported in the 2001 MCBS.  (See 
Appendix Table A2)  We limited our analysis to these 152 unique drugs because of the time 
demands in collecting data from the CMS Medicare.gov website.5   
 
The sample includes drugs from 14 complete drug classes in the USP model formulary 
guidelines developed for and adopted by CMS as the standard drug classification system for 
Medicare drug plan formularies.  We selected some classes based on the volume of drugs 
prescribed, such as cardiovascular drugs, and others based on cost, such as drugs used to 
treat osteoporosis and rheumatoid arthritis.  For simplicity, we have arranged these drugs 
into 10 group for this report.  (See Appendix Table A3)  To augment these groups, our 
sample also includes the top 10 brand-name drugs and the top 10 generic drugs used by 
beneficiaries (as determined by volume of prescriptions from the Medicare prescription drug 
discount card program)6 and an additional set of commonly prescribed drugs that are listed 
on at least one of several lists of commonly prescribed drugs.  Overall, our sample is almost 
evenly divided between generic (n=73) and brand-name (n=79) drugs.7   
 
Data Collection and Analysis 
 
We collected three types of data for each drug from the Formulary Finder on the 
Medicare.gov website:  whether a drug was on plan formularies, the cost-sharing tier for 
each covered drug, and whether utilization management tools (prior authorization, quantity 
limits, or step therapy) were applied.8  These data were collected between late November 
and early December 2005.  
 
                                                 
5 CMS has since released public use files which may make it easier to download and analyze data for all covered 
drugs, across all PDP and MA-PD plans in the future. 
6 The list of most commonly prescribed drugs in the discount card program was provided by CMS to congressional 
staff, but was not made public available on the CMS website. 
7 In most cases, when both a generic and a brand-name version of the same drug are on the market, we included 
only the generic version on our list of drugs.  However, in a few cases, we included the brand-name version to 
examine how likely plans are to include the brand-name drug when a generic equivalent is available.  In these 
cases, the brand-name drug and the generic drug each count as one drug in the sample.  In addition, we included 
both standard-release and extended-release versions of a few drugs and also counted each separately. 
8 In collecting data from the website [http://formularyfinder.medicare.gov/formularyfinder/selectstate.asp], we 
specified the state of Maryland.  We have determined, however, that the organizations offering these national and 
near-national plans used the same formularies in all regions. 
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To estimate beneficiary cost sharing for each drug, we collected information on plan benefit 
designs, including the copayments and coinsurance charged by each plan.9  We used the 
Medicare Prescription Drug Plan Finder on the Medicare.gov website to identify each plan’s 
negotiated price for purchases at retail pharmacies (the price charged to beneficiaries when 
in the deductible period and the coverage gap).10  We used this information to calculate cost 
sharing in the initial coverage period.  When drugs were on a tier with flat copayments, we 
applied the plan’s copayment unless the plan’s negotiated price was lower.  In those cases, 
we set the beneficiary’s cost as the lower of the two prices.  Although plans are not required 
to follow this rule, it appears that this is how prices are reflected in the Plan Finder.  When 
drugs were subject to coinsurance, we applied the coinsurance rate to the plan’s negotiated 
price to estimate the amount a beneficiary would pay in the initial coverage period.  
 
For each of the individual drugs in our sample, we determined the most common form and 
strength of each drug and the amount of a common month’s supply.  Dose and strength are 
needed to determine cost sharing for covered drugs and the price in the coverage gap.  In 
general, we used the Plan Finder’s preset values for the most common form and strength of 
each drug.  Because the Plan Finder defaults to 30 pills for a standard month’s supply, in 
some instances it was necessary to determine through various clinical sources which drugs 
were typically taken as a daily dose, several doses per day, or a single dose per week and 
modify our data collection accordingly.  Negotiated price data were downloaded in 
December 2005.  We rechecked prices for the top 10 brand-name and top 10 generic drugs 
in February 2006 to determine whether there had been changes in the intervening months 
that might negate any of our key findings.  For this subset of drugs, we identified price 
changes for 69 percent of the data points (54 percent increases and 15 percent decreases).  
In general, these changes were very modest – across the 14 organizations in our study, the 
average negotiated price for this set of 20 drugs rose by $1.47, or 3.4 percent.11  Some of 
these price changes (in particular, the large increases or decreases) are likely to reflect 
corrections of errors in data that were posted on the Plan Finder, either in December or in 
February.12  The findings presented in this report reflect the negotiated price data collected 
in December.   
 
 
                                                 
9 Information on benefit design (including cost sharing levels) was collected primarily from the Medicare.gov 
website and supplemented by information from plan websites where the Medicare.gov information was incomplete. 
10 To collect price information from the website 
[https://www.medicare.gov/MPDPF/Public/Include/DataSection/Questions/Questions.asp], we entered a specific zip 
code in Maryland, but did not select a specific pharmacy.  We found that all organizations had a single price across 
different plan options. 
11 The average negotiated price increased for 12 of the 14 organizations and decreased for the other two; the 
largest increase for any organization was 9.8 percent.   
12 It appears that some pricing errors result from prices that are imputed by CMS, typically in cases where plans 
did not submit negotiated prices for off-formulary drugs. 
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RESULTS 
 
 
COVERED DRUGS 
 
Our analysis finds substantial variations in plan formularies and the placement of 
covered drugs on tiers (preferred versus non-preferred versus specialty tier).   
All of the Medicare drug plans examined in this study use formularies to help manage drug 
utilization and costs, but there are significant differences across plans with respect to 
covered drugs.   
 
• The Medicare drug plans that we analyzed cover, on average, 81 percent of the 152 
drugs in our sample, ranging from 64 percent in the most restrictive formulary to 97 
percent in the least restrictive formulary.  No plan covers all 152 of the sample drugs; 
43 percent of plans cover more than 80 percent. (See Exhibit 1) 
 
• Roughly one-third (53) of the 
152 sample drugs are covered 
by all the plans that we 
analyzed.  This list is 
dominated by generic drugs.  
Nearly three-fifths (43) of the 
generic drugs on our list are 
covered by every drug plan 
that we analyzed, but only 10 
of the 79 brand-name drugs in 
our sample are always 
covered.  
 
• All of the top 10 most 
commonly prescribed generic 
drugs are covered by 32 of the 
35 plans.  Levothyroxine is the 
only one of the top 10 
generics not covered by three plans.13  In contrast, only 18 of the 35 plans cover all top 
10 brand-name drugs and only two of the top 10 brand-name drugs are covered by all 
plans. The top 10 brand-name drugs most frequently omitted, in favor of therapeutically 
similar alternatives, include Nexium, Zocor, Diovan, and Plavix.   
 
• Seven of the 14 national and near-national organizations use at least two different 
formularies for their different Medicare drug plan options.14  For six of these 
organizations, the plan with the lowest premium covers fewer of our sample drugs than 
the same organization’s higher-premium plans.  For example, one company’s lowest-
premium plan covers 103 of the 152 drugs in our sample, while its higher-premium 
plans cover 141 of the 152 drugs.  
 
                                                 
13 Levothyroxine products existed prior to 1938, and are thus not subject to official FDA criteria for bioequivalence. 
As a result, use of brand-name and generic products has been controversial.  “Bioequivalence of generic and 
brand-name levothyroxine,” B. Dong et al., JAMA . 277:1205-13. April 16, 1997. 
14 Of the other seven organizations, three offer only one plan, and four use the same formulary for all of their 
plans. 
Cumulative 
Number of 
Plans
Cumulative 
Percent of 
Plans
All 152 0 0%
More than 90% 13 37%
More than 80% 15 43%
More than 70% 27 77%
More than 60% 35 100%
All Top 10 Brands 18 51%
All Top 10 Generics 32 91%
SOURCE: Authors' analysis of drug coverage in stand-alone PDPs 
offered by 14 national and near-national organizations; data from 
Medicare.gov.
Exhibit 1: Number of Plans Covering 152 Sample 
Drugs and Top 10 Brand-Name and Generic Drugs
152 Sample Drugs
Top 10 Brand-Name and Generic Drugs
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The comprehensiveness of formulary coverage varies considerably by drug group.   
 
• Approximately 90 percent of antidepressants, beta blockers, and tumor necrosis factor 
(TNF) inhibitors (used to treat rheumatoid arthritis) are covered on plan formularies 
(averaged across all plans in this analysis); by contrast, roughly 60 percent of hormonal 
(parathyroid and metabolic bone disease) agents and proton pump inhibitors (PPIs) are 
covered by the PDPs that we analyzed. (See Exhibit 2) 
 
EXHIBIT 2: Percent of 152 Sample Drugs Covered, by Drug Group 
SOURCE: Authors' analysis of drug coverage in stand-alone PDPs offered by 14 national and near-national 
organizations; data from Medicare.gov. 
 
• Although CMS guidelines require Medicare drug plans to cover at least two drugs in 
every USP class, one drug in every key type, and “all or substantially all” drugs in 
certain classes, we found that some plans do not cover the drugs that would be 
expected if they were following these guidelines without any exceptions.15  (See 
Appendix B) 
 
º Only 12 of the 35 Medicare drug plans in our analysis cover the expected minimum 
number of required drugs in every class and key drug type in our sample of drugs.  
For example, one plan covers only a single proton pump inhibitor, rather than the 
required two in the class, and three plans do not cover Zetia (for cholesterol), the 
only drug in its key drug type.  Although not all plans meet the standard of coverage 
for expected minimum number of required drugs, no plan covers less than the 
minimum expected number in more than four classes or key drug types.16 
                                                 
15 There are two ways that a plan could be granted exceptions from these rules:  1) plans could design a drug 
classification system different from that developed by USP, which may group drugs differently and lead to a 
different minimum distribution of covered drugs when two are covered in every class; or 2) plans could specifically 
request from CMS an exception from the minimum coverage requirements for specific drugs.  We are unable to 
ascertain whether our finding of noncompliance with formulary guidelines is due to either of these circumstances. 
16 The total would have been significantly different (with fewer plans covering the expected minimum) had CMS not 
recently issued a determination that prescription Niacin (the only product in one of the key drug types for treating 
cholesterol) should be excluded from Part D coverage since it is a vitamin.  Certain drugs, including vitamins, are 
92%
91%
91%
82%
74%
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74%
70%
62%
59%
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Anti-depressants*
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Beta Blockers
Oral Hypoglycemics
Renin-Angiotensin
Anti-dementia Agents
Calcium Channel Blockers
Cholesterol Agents
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Hormonal Agents
 8
º Fifteen plans did not cover all antidepressants, while nine plans did not cover all TNF 
inhibitors, although plans are expected to cover all drugs in these classes.17  A few of 
the antidepressants omitted by some plans do not have major clinical uses, but 
others are important therapeutic agents. 
 
Most Medicare drug plans use some form of tiering structure for drugs on their 
formularies, and there is variation across plans in the number of tiers and the 
number and types of drugs assigned to each tier.18 (See Exhibit 3) 
 
• Three-quarters of the national and near-national plans (24 of 35) use at least a three-
tier cost-sharing structure – typically, Tier 1 for generic drugs, Tier 2 for preferred 
brand-name drugs, and Tier 3 for non-preferred brands.  Fifteen of these plans add a 
specialty tier for certain high-cost drugs.19 
  
• Nine plans use two tiers for the majority of their drugs (Tier 1 for generic drugs and Tier 
2 for brand-name drugs); six of these plans add a specialty tier.   
 
• Two plans replicate the “standard” benefit design with regard to cost sharing, using 25 
percent coinsurance for all covered drugs.  Although these standard plans designate 
tiers for their drugs on both plan and Medicare websites, in practice these tiers have no 
effect on beneficiary cost sharing.   
 
• The majority of the Medicare drug plans that we studied (21 of 35) use a specialty tier, 
primarily for biotechnology or injectable drugs.20 
 
º Both the Formulary Finder and the Plan Finder websites designate all formulary tiers 
in numeric order.  Neither the Formulary Finder nor the Plan Finder on Medicare.gov 
explicitly identifies which tier is the plan’s specialty tier, nor the drugs assigned by 
the plan to this tier, despite the distinctive nature of specialty drugs and the 
importance of conveying this information to beneficiaries.  The Final Rule 
implementing the drug law gives plans permission to deny enrollees the right to 
request a tiering exception for drugs on the specialty tier, as they can for drugs 
placed on other tiers.  Because the website displays are ambiguous about which tier 
plans may have designated as their specialty tier, beneficiaries may not know how 
this provision could affect them when they are comparing plans.  
 
• The specialty tier was used for three of the 10 drug groups in our study: hormonal 
agents, calcium channel blockers (one specific drug in that class), and TNF inhibitors.  
However, some plans place even these expensive drugs on tiers for either preferred or 
non-preferred brand drugs.  (See Exhibit 3) 
                                                                                                                                                             
excluded by law from Part D coverage.  We excluded Niacin from our counts of whether plans cover one drug in 
every key drug type.  See CMS Memorandum from Abby Block, Director, Center for Beneficiary Choices to Medicare 
Part D plans on Prescription Niacin products, February 3, 2006. 
17 Among the antidepressants, CMS guidelines allow plans to cover either Lexapro or citalopram; we count a plan 
as covering “all” drugs if they cover at least one of these drugs.  Similarly, our list includes both standard and 
extended-release versions of some antidepressants, but the CMS guidelines do not require plans to cover all 
versions of a drug.  If a plan covered either version of a drug on our list, we count it as covering that drug. 
18 On the Medicare website, tiers are generally only described by number.  To organize our analysis of tier 
placement, we recoded tier information into a standard set of categories.  As a result, we categorize some plans 
with fewer tiers than the actual number of tiers displayed on websites and in other reports that describe these 
plans. 
19 Because the website does not specifically designate which formulary tier might correspond to a plan’s “specialty” 
tier, in our analysis we designated tiers as specialty tiers when they were designated as such by plans on their 
websites or when they shared the characteristics of a specialty tier.  
20 See note 19.  
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• Plans with a third formulary tier for non-preferred covered drugs vary widely in how they 
use that tier, placing anywhere from 7 percent to 38 percent of the sample drugs they 
cover on the non-preferred tier.  Plans are most likely to place expensive drugs on Tier 3 
or on the specialty tier. 
 
• Each of the top 10 brand-name drugs is placed on the preferred tier by a majority of 
plans.  However, for every drug but one (Toprol XL), each of the top 10 brands is placed 
on the non-preferred tier by at least one plan.  Nexium, Lipitor, and Zoloft – each of 
which has significant competitors in their class – are less likely than the other top 10 
brands to appear on the preferred tier. (See Exhibit 4) 
 
• The likelihood that a brand-name drug will be on Tier 2 versus Tier 3 or the specialty tier 
varies by drug group.  (See Appendix B)  
 
º In the anti-dementia, beta blocker, and oral hypoglycemic groups, there are on 
average at least three times as many drugs on Tier 2 as on Tier 3.   
º Cholesterol-fighting bile acid sequestrants and fibrates, sulfonylureas for controlling 
diabetes, and aldosterone receptor antagonists and ACE inhibitors for high blood 
pressure are drug types and classes in which at least half of the on-formulary brand-
name drugs are on Tier 3. 
º TNF inhibitors are three times more likely to be on Tier 3 or the specialty tier than on 
Tier 2. 
 
Name of Drug Group
Tier 1 
(Generics)
Tier 2 
(Preferred 
Brands)
Tier 3 
(Nonpreferred 
Brands)
Specialty 
Tier
Not 
Covered
Anti-dementia Agents 10% 48% 16% 0% 26%
Antidepressants 54% 23% 14% 0% 8%
Beta Blockers 75% 13% 3% 0% 9%
Calcium Channel Blockers 46% 17% 9% 2% 26%
Cholesterol Agents 19% 28% 23% 0% 30%
Hormonal Agents 1% 35% 19% 4% 41%
Oral Hypoglycemics 43% 30% 9% 0% 18%
Proton Pump Inhibitors 12% 28% 22% 0% 38%
Renin-Angiotensin 38% 17% 19% 0% 26%
Tumor Necrosis Factor Inhibitors 0% 25% 12% 54% 9%
TOTAL 44% 23% 13% 1% 19%
Exhibit 3: Formulary Tier Placement of 152 Sample Drugs, by Drug Group
Percent of Drugs in Each Group in Each Formulary Tier, Averaged Across All Plans
SOURCE: Authors' analysis of drug coverage in stand-alone PDPs offered by 14 national and near-national 
organizations; data from Medicare.gov.
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EXHIBIT 4: Tier Placement of Top 10 Brand-Name Drugs 
Number of Drug Plans with Drug on Each Tier 
SOURCE: Authors' analysis of drug coverage in stand-alone PDPs offered by 14 national and near-national 
organizations; data from Medicare.gov. 
 
 
COST SHARING IN THE INITIAL COVERAGE PERIOD21 
 
The amount enrollees pay for covered drugs varies substantially across plans, due 
to variation in tier placement (whether the drug is covered on Tier 1, 2 or 3, or the 
specialty tier) and the amount plans charge for covered drugs based on their 
benefit design for each tier. (See Exhibit 5) 
 
• As noted earlier, the most common cost-sharing arrangement is a three-tier system of 
flat dollar copayments.22 Among the 21 plans with three tiers and flat copayments23, the 
copayment for a 30-day supply varies as follows:   
 
º Median cost sharing for Tier 1 drugs is $5, but ranges from $0 to $10. 
                                                 
21 Cost-sharing amounts presented in this section incorporate both flat copayment amounts and estimated 
coinsurance amounts.  For the two plans that charge coinsurance for all covered drugs and the 22 plans that 
charge coinsurance for at least some drugs, estimated coinsurance amounts for specific drugs were calculated from 
the plan’s coinsurance rate and the negotiated price reported in the Plan Finder.  In addition, for plans that charge 
a flat copayment, we assumed that enrollees would pay the plan’s negotiated price for a drug if that price was 
lower than the plan’s copayment amount.   
22 In the Plan Finder, some plans display more tiers than the effective number of tiers.  For example, Wellcare 
displays two generic tiers – one for preferred generic drugs and one for non-preferred generic drugs.  In each case, 
however, the same copayment applies.  Similarly, some plans that follow the standard benefit design organize 
drugs into multiple tiers even though the standard 25 percent coinsurance applies to each tier.  In our analysis, we 
collapse these tiers into one if the same cost-sharing amount applies to drugs that the plan itself designates in 
separate tiers. 
23 Fifteen of the three-tier plans with flat copayments also include a specialty tier. 
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º Median cost sharing for Tier 2 drugs is $25, but ranges from $15 to $40.   
º Median cost sharing for Tier 3 drugs is $53, but ranges from $40 to $72.50.  
 
• Median cost sharing for preferred and non-preferred brand-name drugs is higher under 
the stand-alone Medicare drug plans than in plans offered to retirees by large private 
sector employers.24 
 
• For the eight plans with two tiers and flat copayments25, cost sharing for a 30-day 
supply varies as follows: 
 
º Median cost sharing for Tier 1 drugs is $6, but ranges between $0 and $15. 
º Median cost sharing for Tier 2 drugs is $28.50, but ranges between $25 and $73. 
 
EXHIBIT 5: Cost Sharing for Covered Drugs by Formulary Tier  
Medicare Drug Plans with 2-Tier and 3-Tier Flat Copayment Formularies 
NOTE: Exhibit excludes six plans that use some form of coinsurance for at least one of their formulary tiers (other 
than the specialty tier). 
SOURCE: Authors' analysis of drug coverage in stand-alone PDPs offered by 14 national and near-national 
organizations; data from Medicare.gov. 
 
• Six plans charge a percentage of the total price of the drug instead of a flat dollar 
amount for at least some covered drugs (other than specialty drugs).  Two of these 
plans follow the standard benefit design with 25 percent coinsurance for all covered 
drugs.  The other four plans base cost sharing for at least some brand-name drugs on 
coinsurance rates that range from 25 percent to 75 percent.  Three of those four plans 
also include a specialty tier. 
 
                                                 
24 According to the 2005 Kaiser/Hewitt Survey on Retiree Health Coverage, median cost sharing for a 30-day 
supply is $10 for generic drugs, $20 for preferred brands, and $40 for non-preferred brands. 
25 Six of the two-tier plans with flat copayments also include a specialty tier. 
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º For the six plans charging coinsurance, the median cost sharing for the 152 drugs in 
our sample (translated from coinsurance rates into dollar amounts) is $19.73.  
Amounts range widely from a minimum of $0.64 to a maximum of $957.56, due to 
the large variation in drug prices.   
º When drugs are divided by tier, underlying drug prices lead to a far wider range of 
coinsurance amounts within each tier than in plans that charge flat copayments.  The 
median calculated coinsurance amounts among plans that use a coinsurance 
structure are $5.21 for drugs on Tier 1 (ranging from $0.64 to $100.39), $20.99 for 
drug on Tier 2 (ranging from $2.21 to $455.54), and $30.50 for drugs on Tier 3 
(ranging from $2.24 to $957.56). 
 
• All of the studied Medicare drug plans that use a specialty tier apply a coinsurance rate 
for drugs placed on this tier.  Of the 21 plans with a specialty tier: 
 
º Thirteen plans apply a 25 percent coinsurance rate to these drugs. 
º Eight plans charge between 30 percent and 33 percent of the cost of drugs on this 
tier, despite CMS guidance that “encourages” plans to set beneficiary coinsurance for 
these tiers no higher than 25 percent.  
º Because these coinsurance rates are applied to relatively high negotiated prices, the 
cost sharing for drugs placed on a specialty tier is also quite high.  For the drugs 
covered on a specialty tier in our sample, cost sharing ranges from $149 to $450. 
 
Tiered cost-sharing arrangements provide strong financial incentives for enrollees 
to switch from a non-preferred to a preferred brand drug, and from a brand-name 
drug to a generic drug, when available.  
 
• The median cost-sharing for a drug on Tier 3 is more than twice the amount for a Tier 2 
drug, and the median cost-sharing for drugs on Tier 2 is four times greater than the 
median for a Tier 1 drug.  However, the sharpness of the incentives varies.  For 
example, one plan in our analysis charges $30 for a Tier 2 drug versus no copayment for 
a generic, while another has a $23 copayment for Tier 2 and $10 for Tier 1. 
 
• For two plans that use coinsurance for their Tier 3 drugs, the coinsurance rate for the 
specialty tier is actually lower than that for the third tier (25 percent for the specialty 
tier compared to a range of 40 to 75 percent for Tier 3). 
 
The amount enrollees could pay for a given drug when it is covered on the plan’s 
formulary varies considerably across Medicare drug plans.  Some of this variation 
results from placement of brand-name drugs on non-preferred versus preferred tiers, or on 
specialty tiers, which typically results in higher cost-sharing for enrollees when the 
underlying price of the drug is high. 
 
• Among the top 10 brand-name drugs, an enrollee could pay as little as $15 for a 30-day 
supply of Actonel under one plan, but more than four times as much ($66) in another.  
Similar differences can be seen for other drugs, such as Diovan, Fosomax, and Zocor.  
(See Exhibit 6) 
 
• A more dramatic example of this variation across plans is for Enbrel (a TNF inhibitor to 
treat rheumatoid arthritis, among other conditions), with cost sharing that varies from a 
low of $20 in one Medicare drug plan to $1,276 in a plan that covers it but places it on a 
75-percent coinsurance tier.   
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EXHIBIT 6: Cost Sharing for Top 10 Brand-Name Drugs Across Sample Medicare Drug Plans 
Including Covered and Non-Covered Drugs 
NOTE: * indicates drug covered by all plans. 
SOURCE: Authors' analysis of drug coverage in stand-alone PDPs offered by 14 national and near-national 
organizations; data from Medicare.gov. 
 
The spread between the lowest and highest amounts that enrollees could pay out 
of pocket for a given drug is even greater when some plans leave the drug off their 
formularies.  (See Exhibit 6 and Appendix Table A4)  
 
• Other than for some relatively inexpensive drugs, the differential across plans between 
low and high costs for a particular drug grows even larger when comparing costs 
between plans that do and do not place the drug on their formulary.  
 
º For example, in the case of Zocor, the maximum amount paid out of pocket rises 
from $93.35 (when placed on formulary) to $153.12 (when off formulary).  
 
º In a more extreme example, an enrollee could pay a flat copayment of $20 for a 
month’s supply of Zometa (a hormonal agent used for cancer patients) in one plan 
that covers the drug or a $275 coinsurance amount in another plan that also covers 
the drug, but $1,003 for a month’s supply in a plan that does not include the drug on 
its formulary.   
 
Within drug classes, plans have made coverage and tiering decisions that result in 
substantial differences in cost sharing for individual drugs across plans.  (See 
Appendix B) 
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Drugs are categorized in the same class when they are therapeutically similar.  With some 
exceptions, plans could elect not to cover all competing products in a class.  For 
beneficiaries already stabilized on certain medications, patients and their doctors could be 
willing to switch among competing products.  The potential for switching and the costs 
associated with this could be influenced greatly by plans’ decisions with regard to the 
placement of therapeutically similar drugs on their formularies.   
 
• Among the statins used to treat high cholesterol, six of 14 plans include all six 
therapeutic alternatives26, but six plans cover no more than three of these 
medications.27  (See Exhibit 7)  Enrollees in the plans that cover all six drugs can achieve 
savings by choosing the one generic option (lovastatin) or a preferred brand product, 
while enrollees in plans that offer more limited coverage of statins could save over $100 
by choosing an on-formulary drug over off-formulary alternatives.  
 
• Formularies are generally more restrictive with regard to coverage of proton pump 
inhibitors (PPIs) used to treat certain gastrointestinal ailments, perhaps based on clinical 
evidence suggesting the relative comparability of these products.  (See Exhibit 8)  Only 
one plan places all five alternatives on its formulary28 and two plans cover four out of 
five.  Beneficiaries could achieve savings of $100 or more by choosing a plan with their 
drug in a preferred tier or by asking their doctors to switch their prescription to an 
alternative product.  
 
 
 
                                                 
26 Crestor, Lescol, Lipitor, Pravachol, and Zocor are the brand-name competitors; Altoprev and Mevacor are 
branded generic versions of the multi-source generic drug lovastatin. 
27 In order to simplify the display of information, we have focused for this analysis on one plan (specifically the 
lowest-premium plan or only plan) for each of the national or near-national organizations.  Some of the higher-
premium plans have more extensive formularies. 
28 Aciphex, Nexium, Prevacid, Prilosec, and Protonix are the brand-name competitors; omeprazole is the generic 
equivalent of Prilosec. 
Name of Plan
Alto-
prev1 Crestor Lescol Lipitor
Lova-
statin1 Mevacor1
Prava-
chol Zocor
Aetna Essentials $93 $81 $58 $25 $5 $69 $132 $25 
Caremark Silverscript $100 $20 $14 $18 $9 $88 $140 $153 
Cigna Value $40 $40 $20 $40 $4 $24 $40 $20 
Coventry AdvantraRx Value $10 $81 $58 $74 $123 $89 $132 $42 
Humana Standard $23 $20 $14 $18 $8 $17 $33 $33 
Medco $17 $17 $43 $17 $4 $89 $99 $17 
MemberHealth CCRX Basic $102 $101 $72 $19 $0 $91 $142 $34 
Pacificare Saver $100 $99 $70 $53 $8 $89 $140 $22 
Prescription Pathway Bronze $94 $20 $58 $18 $12 $89 $34 $135 
Sterling $47 $25 $25 $25 $10 $89 $66 $67 
Unicare Medicare Rx Rewards $93 $81 $58 $25 $5 $17 $132 $25 
United AARP $55 $55 $55 $28 $5 $89 $55 $28 
United American $30 $30 $58 $30 $9 $89 $60 $30 
Wellcare Signature $99 $97 $69 $66 $0 $88 $139 $66 
Exhibit 7:  Coverage and Cost of Statins for Treating High Cholesterol, by Plan
NOTE: Shaded cell indicates off-formulary drug for specific plan.
1: Altoprev and Mevacor are branded generic versions of the generic lovastatin. 
SOURCE: Authors' analysis of drug coverage in stand-alone PDPs offered by 14 national and near-national organizations; 
data from Medicare.gov. Plans included represent the lowest-premium (or only) plan for each of the 14 organizations in the 
study.
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• The most commonly prescribed brand-name products, as well as competing generic 
alternatives, appear most likely to be included on plan formularies. 
 
º Among the statins, Lipitor, Zocor, and generic lovastatin are on nearly all plan 
formularies, although some plans place only one of the two competing brands on a 
preferred tier.  The less commonly prescribed competitors (Crestor, Lescol, and 
Pravachol) are omitted from about half of the plan formularies. 
 
º Nexium, Prevacid, and the generic omeprazole are the PPIs most likely to be on 
formulary, while Aciphex is off formulary for 11 of 14 plans. 
 
• The brand-name versions of drugs with generic equivalents are more often than not 
excluded from plan formularies. 
 
º Thirteen of 14 plans offer generic lovastatin as the least expensive alternative among 
the statins, but about half the plans make at least one of the brand-name versions of 
lovastatin (Altoprev or Mevacor) available at relatively low prices as well.  Only one 
plan offers a branded generic version for a cheaper price than the generic. 
 
º Only five of 14 plans included the brand-name version of omeprazole (Prilosec) on 
formulary.  The smallest price difference between the brand and generic alternatives 
for a one-month supply is $15 ($25 for the brand versus $10 for the generic). 
 
Typical cost sharing in Medicare drug plans is often more than 25 percent of the 
total cost of covered drugs in the initial coverage period, across the set of drugs 
we studied.29  While individuals may expect to pay 25 percent of drug costs based on their 
understanding of the standard drug benefit ($250 deductible and 25 percent coinsurance), 
                                                 
29 This cost sharing rate is measured as the amount enrollees are expected to pay in the initial coverage period 
(before the doughnut hole) as a share of the plan’s negotiated price reported on the Medicare Drug Plan Finder. 
Name of Plan Aciphex Nexium
Omepra-
zole1 Prevacid
Prilosec 
CR Protonix
Aetna Essentials $130 $132 $66 $25 $176 $25 
Caremark Silverscript $144 $33 $9 $33 $44 $129 
Cigna Value $40 $40 $135 $40 $206 $20 
Coventry AdvantraRx Value $130 $132 $136 $163 $206 $42 
Humana Standard $32 $33 $10 $33 $44 $26 
Medco $145 $17 $4 $17 $71 $129 
MemberHealth CCRX Basic $147 $33 $0 $165 $209 $27 
Pacificare Saver $129 $22 $8 $132 $207 $22 
Prescription Pathway Bronze $132 $33 $8 $34 $178 $107 
Sterling $145 $25 $10 $25 $25 $130 
Unicare Medicare Rx Rewards $130 $132 $5 $25 $176 $25 
United AARP $55 $28 $5 $55 $207 $28 
United American $145 $30 $9 $30 $60 $130 
Wellcare Signature $143 $165 $0 $162 $205 $66 
Exhibit 8:  Coverage and Cost of Proton Pump Inhibitors for Treating Gastrointestinal 
Conditions, by Plan
NOTE: Shaded cell indicates off-formulary drug for specific plan.
1: Prilosec is the brand-name version of the generic omeprazole.
SOURCE: Authors' analysis of drug coverage in stand-alone PDPs offered by 14 national and near-national 
organizations; data from Medicare.gov. Plans included represent the lowest-premium (or only) plan for each of the 
14 organizations in the study.
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our analysis indicates that cost sharing for specific drugs can deviate considerably from the 
standard 25 percent amount.  It appears that many plans have made a tradeoff in benefit 
design for 2006 by reducing or eliminating the deductible; in this case, for a benefit design 
to be actuarially equivalent to the standard benefit, average cost sharing in the initial 
coverage period must be higher than 25 percent. 
 
Across all on-formulary drugs in our sample, our analysis shows: 
 
• Median cost sharing is 32 percent of the negotiated price for all covered drugs.  
(See Exhibit 9)   
 
º Medicare drug plans charge, on average, more than half of the drug’s negotiated 
price for about one-third of the 152 sample drugs (24 of the 73 generic drugs and 28 
of the 79 brand-name drugs). 
 
EXHIBIT 9: Cost Sharing as a Percent of Negotiated Price for Covered Sample Drugs 
SOURCE: Authors' analysis of drug coverage in stand-alone PDPs offered by 14 national and near-national 
organizations; data from Medicare.gov. 
 
• For the 73 generic drugs in our sample, median cost sharing is 27 percent of the 
negotiated price. 
 
º For the top 10 generic drugs, median cost sharing is 62 percent of the negotiated 
price. 
º For four of the top 10 generic drugs, the median cost sharing faced by plan enrollees 
is the full cost of the drug. 
 
• For the 79 brand-name drugs, median cost sharing is 35 percent of the negotiated price.   
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º For the top 10 brand-name drugs, median cost sharing is 38 percent of the 
negotiated price. 
 
An analysis of prices for our sample drugs posted on the Medicare Prescription 
Drug Plan Finder shows there is relatively modest variation across plans in the 
amount enrollees pay for covered drugs when they are required to pay 100 
percent of the cost (in the deductible and doughnut hole) – much less variation 
across plans than other parameters in this analysis.30  Looking forward, a key 
question is whether plans with relatively higher enrollment than other plans will be able to 
use this volume as leverage to offer enrollees prices that are lower than what their 
competitors offer.   
 
• The median negotiated price for the 152 sample drugs ranges from $45.74 for the 
organization with the lowest overall prices to an average of $56.22 for the organization 
with the highest prices – a swing of about 10 percent from the middle of the distribution 
(See Exhibit 10). 
 
º For brand-name drugs in particular, variation across plans is minimal.  When total 
negotiated prices of the brand-name drugs in our sample are examined by 
organization, the organization with the lowest median prices ($85.80) and the 
organization with the highest prices ($96.68) are each about six percent from the 
middle.   
º For the 10 most commonly prescribed brand-name drugs, the range of prices across 
the 14 organizations for a one-month prescription is often quite modest.  (See 
Exhibit 11)  Some of the drugs with relatively small differences include Actonel 
($64.51 to $71.90), Lipitor ($69.12 to $76.22), and Zoloft ($73.91 to $80.48).   
º For generic drugs, variation in negotiated prices is much greater in percentage 
terms, with the 14 organizations in our study ranging from median prices of $13.21 
(27 percent below the middle) to $23.27 (28 percent above).  (See Exhibit 11)  
Although the percentage difference is greater for generics than for brands, the 
difference in dollar terms is similar because the absolute prices for generics are 
lower.  Examples of these ranges can be found among some of the 10 most 
commonly prescribed generic drugs:  Atenolol ($3.26 to $9.66), Lisinopril ($6.68 to 
$24.38), and Warfarin ($9.86 to $27.02).   
                                                 
30 As described above, these prices are indicated on the Medicare Prescription Drug Plan Finder website as prices 
charged by plans in the deductible and the coverage gap, where applicable.  In most cases, they represented 
negotiated prices reported by the plans (likely without regard to rebates negotiated between plans and drug 
manufacturers).  It appears that CMS has imputed some prices for off-formulary drugs in cases where they were 
not supplied by plans. 
EXHIBIT 10: Range of Median Negotiated Prices for Sample Drugs
Median 
Organization
Median of  
organization’s 
negotiated 
prices
Median of  
organization’s 
negotiated 
prices
% difference 
from median 
organization
Median of  
organization’s 
negotiated 
prices
% difference 
from median 
organization
All drugs $49.82 $45.74 -8% $56.22 13%
Generic drugs $18.11 $13.21 -27% $23.27 28%
Brand-name drugs $92.16 $85.80 -7% $96.68 5%
Organization with LOWEST 
Median Price 
Organization with HIGHEST 
Median Price
SOURCE: Authors' analysis of drug coverage in stand-alone PDPs offered by 14 national and near-national 
organizations; data from Medicare.gov.
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• No differences in negotiated prices were found based on the placement of brand-name 
drugs on preferred vs. non-preferred tiers. 
 
• Among our sample drugs, the average negotiated price for on-formulary drugs is 15 
percent lower than the average negotiated price for off-formulary drugs.  It is possible 
that this price difference is a result of CMS imputing prices for some drugs, because 
plans were not required to report prices for off-formulary drugs.  However, the 
Medicare.gov website does not denote when prices have been imputed.  The price 
differential between formulary and non-formulary drugs is greater, in percentage terms, 
for generic drugs (29 percent less expensive) than brand-name drugs (9 percent less 
expensive).  However, the magnitude of the price differential for generic drugs 
translates into relatively small dollar values, because generics are generally less 
expensive than brand-name drugs.  
 
UTILIZATION MANAGEMENT TOOLS 
 
There is significant variation across plans in the application of utilization 
management tools that affect access to drugs, including which tools plans use and 
whether they ever use more than one strategy at once on a single drug.  At this 
point, little is known about how these utilization management tools will be applied, and the 
extent to which they may deter beneficiaries from getting needed prescriptions. 
 
Top 10 Brands
Lowest 
Price Median
Highest 
Price
High-Low $ 
Difference
High-Low % 
Difference
Actonel $64.51 $69.98 $71.90 $7.39 11%
Diovan $46.98 $50.12 $65.83 $18.85 40%
Fosamax $65.15 $69.99 $71.91 $6.76 10%
Lipitor $69.12 $71.18 $76.22 $7.10 10%
Nexium $78.11 $131.67 $164.52 $86.41 111%
Norvasc $58.62 $62.44 $64.34 $5.72 10%
Plavix $118.72 $121.30 $154.93 $36.21 31%
Toprol XL $21.68 $25.77 $28.11 $6.43 30%
Zocor $110.31 $133.70 $153.12 $42.81 39%
Zoloft $73.91 $78.69 $80.48 $6.57 9%
Top 10 Generics
Lowest 
Price Median
Highest 
Price
High-Low $ 
Difference
High-Low % 
Difference
Atenolol $3.26 $4.19 $9.66 $6.40 196%
Furosemide $4.03 $4.60 $13.10 $9.07 225%
Hydrochlorothiazide $2.66 $3.14 $5.21 $2.55 96%
Hydrocodone/Acetaminophen $3.68 $4.58 $5.51 $1.83 50%
Levothyroxine $5.84 $9.08 $12.14 $6.30 108%
Lisinopril $6.68 $10.35 $24.38 $17.70 265%
Metformin $10.17 $14.06 $23.34 $13.17 129%
Metoprolol Tartrate $3.83 $5.13 $15.94 $12.11 316%
Potassium Chloride CR $12.55 $19.95 $36.74 $24.19 193%
Warfarin $9.86 $12.92 $27.02 $17.16 174%
EXHIBIT 11: Range of Median Negotiated Prices for Top 10 Brand-Name and 
Generic Drugs
SOURCE: Authors' analysis of drug coverage in stand-alone PDPs offered by 14 national and near-national 
organizations; data from Medicare.gov.
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• Four of the 35 plans offered on a national or near-national basis use these tools on 10 
percent or less of their covered drugs, while 13 plans apply utilization management 
practices to at least 25 percent of their covered drugs. 
 
º Seven plans never apply more than one utilization management strategy to a single 
drug, while three plans do use all three tools on at least one of the drugs in our 
sample.   
 
Plans are more likely to establish quantity limits for covered drugs than to require 
step therapy, which is required slightly more often than prior authorization. 
 
• On average across the Medicare drug plans and sample drugs that we studied, 14 
percent of covered drugs are subject to quantity limits, seven percent are subject to 
step therapy, and six percent to prior authorization.  (See Exhibit 12) 
 
• Utilization management tools are more commonly applied to brand-name drugs than 
generic drugs.  At least half of the plans use these tools on five of the top 10 brand-
name drugs – most often, quantity limits.  Specifically, two hormonal agents used to 
treat osteoporosis (Actonel and Fosamax), two statins for treating cholesterol (Lipitor 
and Zocor), and one drug for gastrointestinal ailments (Nexium) are most likely to have 
quantity limits applied; Diovan (for hypertension) and Nexium are most likely to have 
step therapy requirements; and Nexium is most likely to require prior authorization. 
 
• Restrictions are far less common for the top 10 generic drugs.  Only two of the top 10 
generic drugs are subject to utilization management practices, and only 12 plans restrict 
the use of either or both of these drugs.  Lisinopril, like other ACE inhibitors, is subject 
to either step therapy or quantity limits.  Several plans place quantity limits on 
hydrocodone, an addictive and commonly abused painkiller. 
 
The use of restrictions varies across groups of drugs.   
 
• Among the ten drug groups analyzed in this paper, utilization restrictions are most 
commonly imposed on TNF inhibitors (most often, prior authorization), PPIs (quantity 
limits), hormonal agents (quantity limits), and renin-angiotensin drugs (step therapy), 
and are least common for beta blockers, calcium channel blockers, and oral 
hypoglycemics (used to treat diabetes).  (See Exhibit 12) 
Name of Drug Group
Prior 
authorization
Quantity 
limits
Step 
therapy
Any UM tool 
applied
Anti-dementia Agents 20% 13% 0% 27%
Antidepressants 2% 12% 9% 19%
Beta Blockers 0% 2% 1% 3%
Calcium Channel Blockers 0% 8% 0% 8%
Cholesterol Agents 2% 32% 3% 36%
Hormonal Agents 20% 28% 0% 43%
Oral Hypoglycemics 2% 8% 4% 13%
Proton Pump Inhibitors 33% 51% 24% 69%
Renin-Angiotensin 1% 16% 31% 48%
Tumor Necrosis Factor Inhibitors 86% 15% 0% 86%
TOTAL 6% 14% 7% 24%
Exhibit 12: Application of Utilization Management Tools, by Drug Group
Percent of Covered Sample Drugs in Each Group Subject to Utilization Management, 
Averaged Across All Plans
SOURCE: Authors' analysis of drug coverage in stand-alone PDPs offered by 14 national and near-national 
organizations; data from Medicare.gov.
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CONCLUSIONS AND POLICY IMPLICATIONS 
 
 
Our analysis of the formularies and other benefit design features of PDPs offered by 14 
national and near-national organizations that sponsor a vast majority of the Medicare stand-
alone drugs plans available to people on Medicare finds considerable variation across plans 
with respect to virtually every key indicator, including: the comprehensiveness of 
formularies, the treatment of covered drugs as preferred or non-preferred, cost-sharing 
arrangements, the amounts enrollees pay for covered drugs in the initial coverage period, 
and the application of utilization management tools.  Variation in each of these areas could 
have a significant impact on beneficiaries’ access to medications and their out-of-pocket 
expenditures over the course of the year.     
 
From a consumer perspective, our findings confirm the complexity of the Medicare 
marketplace and underscore the importance of making careful decisions when choosing 
among the many Medicare drug plans.  Comparing plans along a number of dimensions is 
especially important for beneficiaries with high-cost illnesses for which they use one or more 
drugs that are more likely to be placed on a higher cost-sharing tier or specialty tier – if the 
drugs are covered at all.  The complexity of these comparisons across a large number of 
plans poses a challenge to beneficiaries.  Without careful consideration of the ways in which 
plans differ with respect to these benefit design details, beneficiaries may find themselves 
paying hundreds, if not thousands, of dollars more to fill their prescriptions, depending upon 
which plan they select.  For several commonly used brand-name drugs, enrollees could face 
a four-fold difference in cost sharing for a 30-day supply from one plan to another, even 
when the drug is covered by both plans, and filled at a network pharmacy.  In the case of 
certain high-cost drugs, such as TNF inhibitors (used by people with rheumatoid arthritis, 
among other conditions), the cost-sharing differences across plans are even more extreme.   
 
In addition to examining plan formularies and cost-sharing requirements, the results of this 
study suggest that beneficiaries should also carefully inspect whether and how plans apply 
utilization management tools to the drugs they take.  Prior authorization, step therapy, and 
quantity limits can be used effectively by plans to manage utilization of drugs that are 
subject to overuse or abuse, or where use should be restricted to certain types of 
beneficiaries with specific health conditions.  However, the application of these utilization 
management tools might have the practical effect of making plan formularies less generous 
than they appear.  Further monitoring is needed to assess how these tools are being used 
and whether they impose undue hardship on enrollees.  
 
Even if beneficiaries are able to sort through the variation in formularies, cost sharing, and 
other benefit features and find a Medicare drug plan that meets their needs, their choice is 
based only on their prescription drug needs at the time they enroll.  A Part D plan enrollee 
can not be certain that their chosen plan will meet their needs if their health status changes 
mid-year or the need arises for new medications that they did not take when they enrolled 
in a particular plan.  Moreover, plans are able to change their formularies throughout the 
year, while enrollees are generally locked into their plan for the remainder of the year.  So 
although the choice of plan is made at a single point in time, the potential exists at any time 
during the year for changes to an enrollee's drug needs as well as their plan's formulary.  
The static nature of the enrollment decision, combined with the dynamic nature of both an 
enrollee's health status and the drugs covered by their plan, could lead to some 
beneficiaries lacking access to drugs they need after they have enrolled in a particular plan. 
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The feature that varied the least across plans in our analysis was the negotiated price that 
individuals pay for our sample of drugs when they are responsible for all of their drug costs 
– generally in the deductible period and in the doughnut hole.  The hypothesis is that larger 
or more established organizations will be able to negotiate larger price discounts or rebates 
from drug manufacturers, based on expected volume.  Yet we found minimal variation in 
negotiated prices, especially for brand-name drugs.  These results call into question the 
degree to which competition among the organizations offering drug plans has produced 
lower negotiated drug prices for enrollees thus far.  Future research should monitor whether 
plans with a higher concentration of enrollees offer lower negotiated prices than their 
competitors.   
 
Our results also raise a question about whether plan sponsor organizations (or the 
companies purchasing drugs on their behalf) might favor rebates over drug price discounts 
at the point of sale in their negotiations with pharmaceutical manufacturers.  For 2006 it 
appears that plans may be using negotiated rebates as a way to offset deductibles (and 
likely also premiums) – features that are more apparent to consumers upfront – rather than 
offering lower prices that beneficiaries would pay in the doughnut hole.  This would indicate 
that competition among plans for enrollment – at least for 2006 – is based more on 
premiums than drug prices.  These questions cannot be tested empirically at this time, due 
to a lack of transparency and publicly available data related to price negotiations between 
plan sponsoring organizations and manufacturers.   
  
From a policy perspective, the findings of our study confirm the importance of careful 
oversight in monitoring plan compliance with the law, the final regulations implementing the 
MMA, and other official guidelines related to the design of formularies, cost sharing, and 
actuarial equivalence.  Our analysis suggests that some plans do not meet all of the 
formulary coverage standards established by CMS (e.g., covering the minimum number of 
drugs in a class or category or covering most or all drugs in the six key classes designated 
by CMS in the formulary guidelines).  Although in some cases CMS may have granted 
approval for exceptions to the guidelines, it is possible that such exceptions could create an 
uneven playing field for plans.  Our finding that median cost sharing across the plans in our 
analysis is greater than 25 percent for our sample drugs suggests that the federal 
government will need to be diligent on the issue of determining actuarial equivalence to 
ensure that beneficiaries and the Medicare program are getting the best possible value from 
plans, as well as what the law requires. 
 
Our results also confirm the need for special attention to the placement of drugs on higher 
cost-sharing tiers and specialty tiers to verify that plans are not systematically 
discriminating against beneficiaries with certain conditions.  High-priced drugs, such as 
those in the TNF inhibitors class, are routinely placed by plans on their highest formulary 
tiers, which in general translates into high cost sharing for the beneficiary.  Accurate risk 
adjustment will be essential to ensure that plans offering relatively generous coverage are 
not penalized for attracting a disproportionate share of beneficiaries who take high-cost 
drugs, and that beneficiaries who enroll in these plans are not penalized with unjustifiably 
higher premiums because they chose a plan that attracted higher-cost beneficiaries.  
Specialty tiers are another feature of plans that should be monitored.  Although relatively 
few drugs in our analysis were assigned to the specialty tier, the use of coinsurance – even 
in plans that use only flat copayments for other tiers – guarantees high cost sharing for 
these drugs.  In addition, the specialty tier is not consistently labeled on the Medicare 
website or elsewhere.  Beneficiaries who are newly prescribed drugs on this tier mid-year 
could face unexpectedly higher cost sharing compared to what they pay out of pocket for 
their other prescriptions.  Yet if they want to request an exception from their plan to get the 
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drug covered on a lower cost-sharing tier, they may be unable to do so, according to a 
provision of the final regulations governing the drug benefit program. 
  
With the large number of Medicare drug plans available in 2006, our analysis illustrates the 
numerous ways in which these plans differ, underscoring the importance for beneficiaries – 
particularly those who rely heavily on medications – of making good plan decisions.  Those 
who try to compare the various features of plans will no doubt face tradeoffs among the list 
of covered drugs, premiums, levels of coverage, cost-sharing amounts, and rules governing 
utilization.  The absence of any standardization for many features of plan benefit design, 
and even some of the basic terminology used to describe the plans, adds to challenges for 
beneficiaries.  Faced with similar problems in the Medigap market years ago, Congress 
responded by creating standard benefit packages to facilitate “apples-to-apples” 
comparisons, and by limiting the range of choices available to beneficiaries.  Given the 
significant needs and vulnerabilities of the Medicare population, our findings confirm the 
importance of federal safeguards and ongoing oversight to minimize unnecessary 
complexity in the drug plan marketplace, and to ensure that all Medicare-subsidized drug 
plans meet minimum standards to provide beneficiaries with good coverage at an affordable 
price.   
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APPENDIX A:  METHODOLOGY 
 
This study provides an in-depth examination of the coverage provided by Medicare’s new 
stand-alone Prescription Drug Plans (PDPs).  Due to data limitations, the analysis focuses on 
a subset of plans, which represent 86 percent of all PDPs nationwide, and a subset of drugs, 
which represent about 60 percent of the total prescription volume for Medicare beneficiaries, 
as reported in the 2001 Medicare Current Beneficiary Survey.  This appendix provides a 
detailed description of the Medicare drug plans selected for this analysis, the methodology 
for selecting the specific drugs that we analyzed, and the procedures used for data 
collection and analysis.   
 
 
Prescription Drug Plans in This Analysis 
 
As described in the report, our analysis focuses on the 35 unique stand-alone prescription 
drug plans (PDPs) offered by the 14 national and near-national organizations that sponsor 
such plans in at least 31 of the 34 regions established by CMS (excluding the territories).  
The list of organizations and plans included in this analysis appears in Table A1 below.  One 
of the near-national organizations is more complex than the others.  Plans marketing under 
the name of Prescription Pathway are available in 32 regions, operating under the names of 
three different subsidiaries (American Progressive Life, Pennsylvania Life, Marquette 
National Life).  In some regions, the organization is represented by a single subsidiary; in 
others, multiple subsidiaries offering nearly identical plans.  
 
As noted in the report, the 14 organizations that sponsor stand-alone prescription drug 
plans account for 1,222 plans – 86 percent of the 1,429 PDPs offered nationwide.31  Our 
analysis excludes the remaining 207 plans (14 percent), which are mainly local plans 
offered in a single region or a smaller number of regions.  We also excluded from this 
analysis prescription drug benefits offered by Medicare Advantage prescription drug (MA-
PD) plans.   
 
These 14 organizations each offer between one and four different plan design for a total of 
35 unique plan options.  CMS announced during the review of plan bids that it would only 
permit three plan options per organization, despite the fact that some organizations had 
submitted as many as five or six options.  Prescription Pathway had more than three options 
approved in some regions because of the way it operates under different subsidiaries.  For 
this analysis, we count Prescription Pathway as offering four plan options (Bronze, Silver, 
Gold, Platinum) since the organization’s other options are nearly exact duplicates of these 
four.  In addition, one national organization (Unicare, sponsored by Wellpoint), offers three 
different plans in most regions but only a single plan option in Region 7.  Finally, we exclude 
from our analysis additional plan options offered on a more limited basis by two of the 
organizations in our study.  Specifically, we exclude additional plans offered by United 
HealthCare in four regions, and plans offered by Coventry under its First Health subsidiary 
in 13 regions.   
 
Although the cost sharing features change from one plan option to another, formularies do 
not always change.  Across the 35 unique plan options, there are 21 unique formularies.  
Four of the organizations with multiple plan options use the same formulary in each plan 
option (Cigna, MemberHealth, United HealthCare, and Humana.  The other seven 
organizations with multiple plan options have two different formularies.  Among the latter 
                                                 
31  The 10 national organizations offer 882 (62 percent) of the 1,429 plans offered nationwide, and the four near-
national firms offer another 340 plans (24 percent) nationwide.   
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cases, some use the alternate formulary just for their highest-premium plan, some use it for 
their two higher-premium plans, and one organization uses it only for its mid-premium plan. 
 
Data on the characteristics of plan benefits were collected from the CMS Medicare 
Prescription Drug Plan Finder website32, when available.  These data were supplemented by 
information (for example, cost sharing amounts for formulary tiers) collected directly from 
plan benefit summary materials and   other documents on each sponsoring organization’s 
website. 
 
 
Sample of Drugs in This Analysis 
 
Selecting the Drug Sample 
 
Given the limited way in which formulary, cost-sharing, and pricing data for drugs were 
publicly available on Medicare.gov at the time of this analysis, the time demands in 
collecting information made it impossible to include the universe of FDA-approved drugs.  
CMS has since released public use files which may make it easier to download and analyze 
data for all covered drugs, across all PDP and MA-PD plans, in the future.  Those files, 
however, are compiled at the level of National Drug Code (NDC) (where each form and 
strength of a drug and each manufacturer are assigned a separate code number), which 
makes analysis challenging.  Also, those files do not contain the pricing information needed 
for this analysis. 
 
We generated the sample of drugs for our analysis with several goals in mind: 1) including 
drugs that are among the most frequently prescribed drugs used by Medicare beneficiaries;  
2) including drugs that belong to certain commonly prescribed drug classes; and 3) 
including a sub-sample of high-cost drugs.  In total, our sample consisted of 152 drugs, 
including 73 generic drugs and 79 brand-name drugs.  Together, these drugs include nearly 
60 percent of the total prescription volume for Medicare beneficiaries, as reported in the 
2001 Medicare Current Beneficiary Survey.33  As a result, this analysis encompasses a 
substantial amount of all drug utilization by beneficiaries.   The full list of drugs in our 
sample appears in Table A2 below. 
 
Most Prescribed Drugs by Medicare Beneficiaries 
 
Our sample of drugs includes the 10 most commonly prescribed brand-name drugs and the 
10 most commonly prescribed generic drugs used by beneficiaries as determined by volume 
of prescriptions from the Medicare-endorsed prescription drug discount card program.34  We 
compared this list of commonly used drugs to another list of most prescribed drugs for the 
total U.S. population (compiled by Verispan) to confirm no unusual characteristics 
associated with purchases through the discount card program.   
 
                                                 
32 http://www.medicare.gov/MPDPF/Public/Include/DataSection/Questions/MPDPFIntro.asp 
33 There is a key methodological issue involved in using the 2001 Medicare Current Beneficiary Survey as a proxy 
for estimating current prescription volume, and that is the real potential for changes in the availability of 
prescription drugs in the intervening years.  At the drug class level, this may be a relatively minor issue, but it 
could be a larger concern at the individual drug level, as brand-name drugs lose patent protection and generics are 
introduced, drugs may be withdrawn from the market for safety reasons, and new drugs are given FDA approval 
and brought to market.   
34 The list of most commonly prescribed drugs in the discount card program was provided by CMS to congressional 
staff, but is not posted on the CMS website. 
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We included in our sample another 15 drugs that appear on one of several lists of the most 
commonly prescribed drugs, but were not in one of the common drug classes described 
below.  These include drugs that are among the 25 most prescribed drugs in the Medicare-
endorsed discount card program, but not included among the top 10 brands or top 10 
generics.  Other added drugs were those ranked among the top 10 brands and generics for 
the general population on the Verispan list (measured by either volume of prescriptions or 
dollars) but not in the discount card program.  These additional 15 drugs include several 
commonly prescribed drugs from the following drug categories:  anti-bacterials, respiratory 
tract agents prescribed for asthma, sedatives, analgesics, and certain cardiovascular 
medications.  Because these are commonly prescribed drugs, they represent a significant 
share of total prescription volume. 
 
Common Drug Groups 
 
We included drugs in our sample that comprised several complete drug groups because 
sponsoring organizations often make coverage decisions in the context of entire therapeutic 
categories and classes of drugs.  In selecting drug groups, we relied on the drug 
classification system developed by the United States Pharmacopoeia (USP) and adopted by 
CMS as the model drug classification system.  According to CMS, a majority of drug plans 
chose to use this system.  The structure of the USP system involves 41 therapeutic 
categories, most of which are further divided into pharmacologic classes.  There are a total 
of 146 unique categories and classes in the USP system.  In addition, many of the 
categories are classes are further divided by USP into key drug types.  Although these are 
not part of the official classification system, they were used by CMS in its formulary 
guidelines. 
 
Our sample includes all drugs from four of the 10 classes of the largest category in the USP 
system, cardiovascular drugs:  
• Beta-adrenergic Blocking Agents (treatments for hypertension, known as beta 
blockers) 
• Calcium Channel Blocking Agents (treatments for hypertension) 
• Dyslipidemics (treatments for high cholesterol) 
• Renin-angiotensin-aldosterone System Inhibitors (treatments for hypertension, 
including ACE inhibitors and angiotensin receptor blockers or ARBs). 
 
Our sample includes all of the drugs in several therapeutic categories, as defined by USP: 
• Antidepressants (including all three classes in this category) 
• Anti-dementia Agents (including all three classes in this category, several of which 
are used to treat Alzheimer’s Disease) 
 
Finally, our sample includes drugs in particular classes or key drug types in the following 
areas: 
• Oral hypoglycemics class of Blood Glucose Regulators (drugs used to treat diabetes) 
• Proton Pump Inhibitors class of Gastrointestinal Agents (drugs used to treat ulcers 
and gastroesophogeal reflux disease or GERD) 
• Parathyroid/Metabolic Bone Disease Agents class of the Hormonal Agents 
(Replacement, Stimulating, Modifying) category (two key drugs types, 
biphosphonates and calcium regulating hormones, in this class that include those 
used to treat osteoporosis) 
• Tumor Necrosis Factor (TNF) Inhibitors, a key drug type in the Immune 
Suppressants class of Immunological Agents category (drugs used to treat 
rheumatoid arthritis) 
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Most of these drug classes were selected based on the volume of drugs prescribed from 
them.  Others (e.g., drugs to treat osteoporosis or rheumatoid arthritis) were selected to 
ensure that the sample included some of very high-cost drugs and some specialty drugs 
(e.g., biotechnology drugs and self-injected drugs). 
 
Drugs omitted from this analysis generally fall into two categories.  There are many drugs in 
clinically important but less commonly prescribed classes of drugs (e.g., HIV/AIDS drugs 
and cancer agents) that we did not select for study.  In addition, there are many alternative 
drugs in classes where we selected a commonly-prescribed drug but have not studied the 
entire class (e.g., antibacterials, analgesics, hormonal agents, and respiratory tract agents). 
 
The placement of the different drug groups in our sample within the USP classification 
system is further outlined in Table A3.  The full listing of drugs in Table A2 shows which 
drugs are in which category, class, and key drug type (where applicable). 
 
Defining and Classifying Drugs 
 
The drug sample selection process as described above identified the chemical entities that 
we studied.  We then determined which version of a drug to include.  Generally, we chose to 
study only the generic version where both a generic and brand-name alternative are 
available.  In order to study how plans make decisions when both versions are available, we 
did include both the brand-name and generic version of a few drugs.  In addition, we chose 
to include a few drugs that are variants of another drug, such as the weekly version of 
Prozac or the continuous-release version of Paxil. 
 
The formulary data available from the Medicare Prescription Drug Formulary Finder35 related 
to coverage, pricing, and utilization management are specified at a more detailed level than 
drug name to include both the form and strength of a medication.  For example, the 
Formulary Finder lists multiple dosages and forms of potassium chloride, including a liquid 
as well as tablets.  Likewise, there are four different strengths of hydrocodone with 
acetaminophen, each having a different combination of dosages for the two drugs.   
 
At least in theory, plans could apply different tier placement or utilization restrictions 
depending on the form or strength of a drug.  Therefore, we established a standard form, 
strength, and monthly dose for each drug.  Because we did not have the resources to collect 
data on every form and strength of all 152 sample drugs, we started from the default form 
and strength offered to consumers on the Medicare.gov website.  Thus, our findings reflect 
only plan coverage information for this specific version of each drug on our list.  Yet plans 
could cover some, all, or none of the different forms and strengths of certain drugs and 
their variants.  Therefore it is possible that some plans that fail to cover the specific version 
of a drug we studied may actually cover another version.  It is also possible that some plans 
cover only the form and strength we studied, but fail to cover other forms or strengths that 
are also widely used by Medicare beneficiaries. 
 
With respect to a 30-day supply, the Formulary Finder includes a default monthly amount of 
30 units for drugs in tablet or capsule form, without regard to whether this is a common 
dosage (defaults are also provided for drugs not in pill form).  In fact, there are several 
cases where the default quantity was inaccurate or inappropriate.  These include drugs that 
are taken less frequently than on a daily basis (e.g., Fosamax, Actonel, Prozac Weekly, 
Enbrel and Remicade) or drugs that are taken several times a day.  In these cases, we 
determined a standard dosage from sources such as rxlist.com and relied on this 
                                                 
35 formularyfinder.medicare.gov/formularyfinder/selectstate.asp 
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information to modify the number of pills obtained per month for over one-third of all the 
drugs on our list.  This information is essential for determining in the Plan Finder the drug’s 
negotiated price for a monthly supply.   
 
Most of the medications on our list are maintenance drugs that would be taken for 
conditions such as hypertension, high cholesterol, or diabetes for the full 12 months of a 
year.  However, our list of commonly prescribed drugs does include a few antibiotics and 
pain medications where patient use does not necessarily follow this pattern.  Since dosing 
for these types of drugs varies considerably according to the type of infection being treated 
or the degree of pain experienced by the patient, we generally settled on a 30-pill supply for 
a month’s prescription.  In some cases, this would represent a two-week course of an 
antibiotic taken two times a day or pain medication taken four times a day for one week. 
 
 
Methodology for Collecting Data on Tier, Price, and Usage Restrictions 
 
Data for this study were collected from the CMS website using the Formulary Finder and 
Medicare Prescription Drug Plan Finder following the November 15, 2005 start of open 
enrollment season.  Once plan enrollment began, plans were not allowed to change their 
formularies, including information about cost-sharing tiers and utilization management 
practices until three months in to 2006 (except where data errors exist).  In a few cases 
where we became aware of systematic errors on the website prior to the completion of our 
analysis, the erroneous data we had already collected were replaced with new, accurate 
information.  This was not a frequent occurrence. 
 
Collecting Information from the Medicare Prescription Drug Formulary Finder 
 
We collected three types of data for each drug from the Formulary Finder for Prescription 
Drug Plans on the Medicare.gov website:  whether a drug was on plan formularies, the cost-
sharing tier for each covered drug, and whether utilization management tools (prior 
authorization, quantity limits, or step therapy) were applied.  For each drug, we used the 
form, strength, and dosage, as described above.  We chose the state of Maryland as the 
point of entry for the website, and we cross-checked tier information for plans in California 
to see if there were any differences.  Since the formularies were the same in both regions, 
we assumed that plans did not vary their formularies from region to region – an assumption 
that was later verified with the CMS public use files.   
 
Tier information on the website is based on the nominal tiers that are listed by the plans.  
As noted in the main report, we preferred to establish a standardized tier designation across 
plans.  Some plans display more tiers than the effective number of tiers with different cost-
sharing characteristics.  For example, Wellcare displays two generic tiers: one for preferred 
generic drugs and one for non-preferred generic drugs.  In each case, however, the same 
copayment applies.  Similarly, some plans that follow the standard benefit design organize 
drugs into multiple tiers even though the standard 25 percent coinsurance applies to each 
tier.  In our analysis, we collapsed these tiers into one if the same cost-sharing amount 
applies to drugs that the plan itself designates in separate tiers.   
 
Similarly, neither plans nor the Medicare website have a systematic means of designating 
specialty tiers, despite the distinctive nature of specialty drugs and certain rules regarding 
appeals and exceptions that apply only to these tiers.  We chose to label tiers as specialty 
tiers if they had coinsurance amounts of between 25 percent and 33 percent, were listed 
separately from other tiers, and contained drugs that were generally characterized as 
specialty drugs. 
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Collecting Information from the Medicare Prescription Drug Plan Finder 
 
We collected price information for purchases at retail pharmacies from the Medicare 
Prescription Drug Plan Finder between November 15, 2005 and January 2006.  Drugs were 
entered in large enough groups to ensure that a hypothetical enrollee would incur expenses 
in the coverage gap so that we could retrieve the plan’s negotiated prices that enrollees 
would pay in the coverage gap or before a plan deductible is met.  We used a zip code in 
Maryland as the point of entry for the website, but did not enter a specific pharmacy.  We 
verified through spot-checking that negotiated prices do not appear to differ across plan 
options when a single organization offers plans with different formularies.  Instead, it 
appears that sponsoring organizations use a single negotiated price list for each of their plan 
options.  As noted in the full report, we did some checking for price changes at a later date. 
 
We then combined data on cost-sharing tiers, utilization management practices, and 
negotiated prices into one data file for analysis.  Cost sharing for each drug was calculated 
based on plan benefit designs and negotiated prices.  Flat dollar copayments for specific 
drugs reflect either the cost sharing amount for the drug’s tier or the actual negotiated price 
of the drug, whichever was lower.36  Cost sharing for specific drugs where a coinsurance 
rate was charged was calculated by multiplying the applicable percentage times the plan’s 
negotiated price for the drug.  Again, the lower of the calculated coinsurance amount or the 
actual negotiated price was used in the analysis. 
 
                                                 
36 Medicare Part D rules do not require that beneficiaries pay the lesser of the copayment or the negotiated price of 
the drug.  But website displays seem to apply this rule in all cases.  Although we have not found this payment rule 
stated explicitly in plan benefit summaries, we assumed for the purposes of our analysis that it applies in all cases. 
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(CONTINUED ON NEXT PAGE) 
Table A2: List of 152 Drugs in the Study Sample
Drug Group/Drug Name Dosage Drug Group/Drug Name Dosage
Aricept 10mg TAB Coreg 25mg TAB
Cognex 10mg CAP LABETALOL HCL 200mg TAB
Exelon 3mg CAP
Razadyne 8mg TAB ACEBUTOLOL HCL 200mg CAP
ATENOLOL* 50 mg TAB
Namenda 10mg TAB BETAXOLOL HCL 10mg TAB
BISOPROLOL FUMARATE 5mg TAB
ERGOLOID MESYLATES 1mg TAB ORAL METOPROLOL TARTRATE* 50mg TAB
Toprol XL* 50mg TAB
CARTEOLOL SOL Ophth 1%
Nardil 15mg TAB Levatol 20mg TAB
Parnate 10mg TAB NADOLOL 40mg TAB
PINDOLOL 5mg TAB
CITALOPRAM HYDROBROMIDE 20mg TAB PROPRANOLOL HCL 20mg TAB
FLUOXETINE 20mg CAP SOTALOL HCL 80mg TAB
FLUVOXAMINE 100mg TAB TIMOLOL MALEATE 0.5% OP SOL
Lexapro 10mg TAB
PAROXETINE 20mg TAB
Paxil CR 25mg TAB
Prozac Weekly 90mg CAP
Zoloft* 100mg TAB Dynacirc 5mg CAP
FELODIPINE ER 5mg TAB
Cymbalta 60mg CAP NICARDIPINE 20mg CAP
Effexor 75mg TAB NIFEDIPINE 10mg CAP
Effexor XR 75mg TAB Nimotop 30mg CAP
NEFAZODONE 200mg TAB Norvasc* 10mg TAB
Sular CR 20mg TAB
AMITRIPTYLINE 25mg TAB
AMOXAPINE 50mg TAB DILTIAZEM HCL 360mg CAP
CLOMIPRAMINE 50mg CAP VERAPAMIL 80mg TAB
DESIPRAMINE 50mg TAB
DOXEPIN 50mg CAP
IMIPRAMINE 25mg TAB
NORTRIPTYLINE 25mg CAP
Surmontil 50mg CAP
Vivactil 10mg TAB
BUPROPION ER 100mg TAB
BUPROPION SR 150mg TAB
MAPROTILINE 50mg TAB
MIRTAZAPINE 15mg TAB
TRAZODONE 100mg TAB
Wellbutrin XL 300mg TAB
NOTE: * indicates top 10 brand-name/generic drug. Brand-name drugs in lowercase, generic drugs in capital letters.
Reuptake Inhibitor:  SSRIs
Reuptake Inhibitor:  SNRIs
Reuptake Inhibitor:  Tricyclics
Other Anti-depressants
Dihydropyridines
Non-dihydropyridines
Cardiovascular: Calcium Channel Blockers
(Hypertension)
 (Hypertension)
Monoamine Oxidase (Type A) Inhibitors
Anti-dementia Agents
(Alzheimer's disease)
Anti-depressants
Cardiovascular: Beta Blockers
Cholinesterase Inhibitors
Glutamate Pathway Modifiers
Other Anti-dementia Agents
Alpha-beta–adrenergic Blocking Agents
Cardioselective Beta-adrenergic Blocking Agents
Nonselective Beta-adrenergic Blocking Agents
 31
(CONTINUED ON NEXT PAGE) 
Table A2: List of 152 Drugs in the Study Sample (continued)
Drug Group/Drug Name Dosage Drug Group/Drug Name Dosage
Aciphex 20mg TAB
CHOLESTYRAMINE 4gm POW Nexium* 40mg CAP
Colestid 1gm TAB OMEPRAZOLE 20mg CAP
Welchol 625mg TAB Prevacid DR 30mg CAP
Prilosec CR 40mg CAP
GEMFIBROZIL 600mg TAB Protonix 40mg TAB
Tricor 145mg TAB
Altoprev ER 60mg TAB
Crestor 10mg TAB
Lescol 40mg CAP Actonel* 35mg TAB
Lipitor* 10mg TAB Aredia 90mg INJ
LOVASTATIN 40mg TAB Didronel 400mg TAB
Mevacor 20mg TAB Fosamax* 70mg TAB
Pravachol 40mg TAB PAMIDRONATE 90mg INJ
Zocor* 20mg TAB Skelid 200mg TAB
Zometa 4mg/5mL INJ
Zetia 10mg TAB
Miacalcin 200iu/mL SPR
Niaspan ER 500mg TAB Forteo 750mcg/3mL SOL
Glyset 25mg TAB
Inspra 25mg TAB Precose 50mg TAB
SPIRONOLACTONE 25mg TAB
METFORMIN* 500mg TAB
Aceon 4mg TAB
Altace 10mg CAP Prandin 2mg TAB
BENAZEPRIL 20mg TAB Starlix 120mg TAB
CAPTOPRIL 25mg TAB
ENALAPRIL 10mg TAB Amaryl 4mg TAB
FOSINOPRIL 20mg TAB CHLORPROPAMIDE 250mg TAB
LISINOPRIL* 10mg TAB GLIPIZIDE 5mg TAB
Mavik 4mg TAB GLIPIZIDE ER 10mg TAB
QUINAPRIL 40mg TAB GLYBURIDE 5mg TAB
GLYBURIDE MICRONIZED 6mg TAB
Atacand 32mg TAB TOLAZAMIDE 250mg TAB
Avapro 150mg TAB TOLBUTAMIDE 500mg TAB
Benicar 20mg TAB
Cozaar 50mg TAB Actos 30mg TAB
Diovan* 80mg TAB Avandia 4mg TAB
Micardis 80mg TAB
Teveten 600mg TAB
Enbrel 25mg INJ
Humira 40mg/0.8 KIT
Remicade 100mg INJ
NOTE: * indicates top 10 brand-name/generic drug. Brand-name drugs in lowercase, generic drugs in capital letters.
(Rheumatoid Arthritis)
(Diabetes)
Alpha Glucosidase Inhibitors
Biguanides
Meglitinides
Sulfonylureas
Thiazolidinediones
Tumor Necrosis Factor Inhibitors
Gastrointestinal Agents: 
Cardiovascular: Renin-angiotensin-
Disease) Agents (Osteoporosis)
Biphosphonates
Calcium Regulating Hormones
Aldosterone Receptor Antagonists
Angiotensin-converting Enzyme (ACE) Inhibitors
Angiotensin II Receptor Antagonists (ARBs)
Proton Pump Inhibitors (Ulcers, GERD)
Hormonal (Parathyroid/Metabolic Bone
Oral Hypoglycemics
Lipid Absorption Inhibitors
HMG CoA Reductase Inhibitors (Statins)
Nicotinic Acid
aldosterone System Inhibitors
(Hypertension)
Cardiovascular: Dyslipidemics
(Cholesterol)
Bile Acid Sequestrants
Fibrates
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Table A2: List of 152 Drugs in the Study Sample (continued)
Drug Group/Drug Name Dosage
Advair Diskus 250/50 MIS
ALBUTEROL 90mcg AER
Ambien 10mg TAB
AMOXICILLIN 500mg CAP
AMOXICILLIN/CLAVULANATE POT 875mg TAB
AMOXICILLIN/POT CLAVULANATE 875mg TAB
Celebrex 200mg CAP
CEPHALEXIN 500mg CAP
CIPROFLOXACIN HCL 500mg TAB
DIGOXIN .125mg TAB
FUROSEMIDE* 40mg TAB
GABAPENTIN 300mg TAB
HYDROCHLOROTHIAZIDE* 25mg TAB
HYDROCODONE/ACETAMINOPHEN* 5-500mg TAB
ISOSORBIDE MONONITRATE 20mg TAB
POTASSIUM CHLORIDE CR* 20meq TAB
LEVOTHYROXINE* 100mcg TAB
Levoxyl 100mcg TAB
Neurontin 300mg CAP
Plavix* 75mg TAB
PREDNISONE 5mg TAB
PROPOXYPHENE-N/ACETAMINOPHEN 100-650 TAB
Synthroid 100mcg TAB
TRIAMTERENE/HCTZ 37.5-25 CAP
WARFARIN* 5mg TAB
Zithromax 200/5mL SUS
Zithromax Z-Pak Z-PAK TAB
NOTE: * indicates top 10 brand-name/generic drug. Brand-name drugs in lowercase, generic drugs in capital letters.
Prescribed Drugs Not in Other Drug Groups
Top 10 Brands/Generics and Other Commonly 
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 (CONTINUED ON NEXT PAGE) 
Drug Name (Drug Group)
Brand/
Generic
Minimum 
Cost 
Sharing 
for Drug 
if Covered
Maximum 
Cost 
Sharing 
for Drug 
if Covered
Maximum 
Cost for 
Drug 
if Not 
Covered
Acebutolol HCL (Beta Blockers) G $0.00 $18.77 $62.42
Aceon (Renin-Angiotensin) B $10.72 $50.16 $52.66
Aciphex (Proton Pump Inhibitors) B $32.38 $92.38 $146.65
Actonel (Hormonal Agents) B* $15.00 $66.00 $70.05
Actos (Oral Hypoglycemics) B $17.00 $70.33 $251.25
Advair Diskus (Other Commonly Used Drugs) B $15.00 $67.84 $213.05
Albuterol (Other Commonly Used Drugs) G $0.00 $10.00 NA
Altace (Renin-Angiotensin) B $13.70 $55.04 $60.17
Altoprev (ER) (Cholesterol Agents) B $0.00 $83.22 $102.01
Amaryl (Oral Hypoglycemics) B $9.09 $45.63 $46.13
Ambien (Other Commonly Used Drugs) B $17.00 $66.00 NA
Amitriptyline (Anti-depressants) G $0.00 $7.50 NA
Amoxapine (Anti-depressants) G $0.00 $27.62 NA
Amoxicillin (Other Commonly Used Drugs) G $0.00 $10.00 NA
Amoxicillin/Clavulanate Potassium (Other Commonly Used Drugs) G $0.00 $29.00 $345.57
Amoxicillin/Potassium Clav (Other Commonly Used Drugs) G $0.00 $100.39 NA
Aredia (Hormonal Agents) B $20.00 $238.79 $843.60
Aricept (Anti-dementia Agents) B $15.00 $66.00 NA
Atacand (Renin-Angiotensin) B $15.48 $62.00 $76.45
Atenolol (Beta Blockers) G* $0.00 $6.04 NA
Avandia (Oral Hypoglycemics) B $15.00 $66.00 NA
Avapro (Renin-Angiotensin) B $11.61 $46.70 $64.78
Benazepril (Renin-Angiotensin) G $0.00 $10.00 NA
Benicar (Renin-Angiotensin) B $11.53 $53.88 $56.38
Betaxolol HCL (Beta Blockers) G $0.00 $13.61 $68.16
Bisoprolol Fumarate (Beta Blockers) G $0.00 $14.30 NA
Bupropion ER (Anti-depressants) G $0.00 $26.44 $94.59
Bupropion SR (Anti-depressants) G $0.00 $29.21 NA
Captopril (Renin-Angiotensin) G $0.00 $4.00 NA
Carteolol (Beta Blockers) G $0.00 $11.20 $21.48
Celebrex (Other Commonly Used Drugs) B $17.00 $66.00 $122.66
Cephalexin (Other Commonly Used Drugs) G $0.00 $10.83 NA
Chlorpropamide (Oral Hypoglycemics) G $0.00 $11.22 $23.07
Cholestyramine (Cholesterol Agents) G $0.00 $12.43 $70.42
Ciprofloxacin HCL (Other Commonly Used Drugs) G $0.00 $14.04 NA
Citalopram Hydrobromide (Anti-depressants) G $0.00 $10.00 $11.72
Clomipramine (Anti-depressants) G $0.00 $13.78 NA
Cognex (Anti-dementia Agents) B $40.00 $134.76 $354.04
Colestid (Cholesterol Agents) B $8.78 $41.04 $41.04
Coreg (Beta Blockers) B $12.55 $50.44 $50.44
Cozaar (Renin-Angiotensin) B $12.10 $66.00 $69.23
Crestor (Cholesterol Agents) B $17.00 $62.00 $100.54
Cymbalta (Anti-depressants) B $17.00 $84.57 $138.59
Desipramine (Anti-depressants) G $0.00 $17.56 NA
Didronel (Hormonal Agents) B $17.00 $106.68 $193.87
Digoxin (Other Commonly Used Drugs) G $0.00 $12.29 $11.79
Diltiazem (HCL) (Calcium Channel Blockers) G $0.00 $20.63 NA
Diovan (Renin-Angiotensin) B* $12.46 $62.58 $62.58
Doxepin (Anti-depressants) G $0.00 $13.65 NA
Dynacirc (Calcium Channel Blockers) B $17.00 $30.00 $143.86
Effexor (Anti-depressants) B $20.00 $83.50 $131.43
Effexor XR (Anti-depressants) B $20.00 $69.40 $92.53
Enalapril (Renin-Angiotensin) G $0.00 $10.00 NA
Enbrel (TNF Inhibitors) B $20.00 $1,276.24 NA
Ergoloid Mesylates (Anti-dementia Agents) G $0.00 $22.96 $103.68
Exelon (Anti-dementia Agents) B $17.00 $71.42 $158.32
Felodipine (ER) (Calcium Channel Blockers) G $0.00 $29.08 $84.72
Fluoxetine (Anti-depressants) G $0.00 $10.00 NA
Fluvoxamine (Anti-depressants) G $0.00 $65.30 NA
Table A4: Minimum and Maximum Costs for 152 Sample Drugs 
(both Covered and Uncovered)
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Drug Name (Drug Group)
Brand/
Generic
Minimum 
Cost 
Sharing 
for Drug 
if Covered
Maximum 
Cost 
Sharing 
for Drug 
if Covered
Maximum 
Cost for 
Drug 
if Not 
Covered
Forteo (Hormonal Agents) B $17.00 $269.32 $657.39
Fosamax (Hormonal Agents) B* $15.00 $66.00 $69.91
Fosinopril (Renin-Angiotensin) G $0.00 $13.40 $32.11
Furosemide (Other Commonly Used Drugs) G* $0.00 $5.49 NA
Gabapentin (Other Commonly Used Drugs) G $0.00 $29.78 $120.80
Gemfibrozil (Cholesterol Agents) G $0.00 $12.82 NA
Glipizide (Oral Hypoglycemics) G $0.00 $4.87 $11.46
Glipizide ER (Oral Hypoglycemics) G $0.00 $11.97 NA
Glyburide (Oral Hypoglycemics) G $0.00 $7.97 NA
Glyburide Micronized (Oral Hypoglycemics) G $0.00 $13.18 $28.64
Glyset (Oral Hypoglycemics) B $15.33 $60.00 $72.38
Humira (TNF Inhibitors) B $17.00 $1,276.25 $1,337.50
Hydrochlorothiazide (Other Commonly Used Drugs) G* $0.00 $5.00 NA
Hydrocodone / APAP (Other Commonly Used Drugs) G* $0.00 $5.51 NA
Imipramine (Anti-depressants) G $0.00 $19.55 NA
Inspra (Renin-Angiotensin) B $25.00 $85.48 $122.14
Isosorbide Mononitrate (Other Commonly Used Drugs) G $0.00 $16.58 NA
Labetalol HCL (Beta Blockers) G $0.00 $15.46 NA
Lescol (Cholesterol Agents) B $14.32 $57.79 $72.07
Levatol (Beta Blockers) B $12.79 $51.39 $60.16
Levothyroxine (Other Commonly Used Drugs) G* $0.00 $10.00 $12.04
Levoxyl (Other Commonly Used Drugs) B $0.00 $16.47 $17.72
Lexapro (Anti-depressants) B $16.94 $67.75 $86.80
Lipitor (Cholesterol Agents) B* $17.00 $66.00 $74.40
Lisinopril (Renin-Angiotensin) G* $0.00 $10.00 NA
Lovastatin (Cholesterol Agents) G $0.00 $15.42 $122.54
Maprotiline (Anti-depressants) G $0.00 $20.90 $19.98
Mavik (Renin-Angiotensin) B $8.31 $48.87 $51.37
Metformin (Oral Hypoglycemics) G* $0.00 $10.16 NA
Metoprolol Tartrate (Beta Blockers) G* $0.00 $10.00 NA
Mevacor (Cholesterol Agents) B $17.18 $68.73 $90.94
Miacalcin (Hormonal Agents) B $17.00 $66.00 $86.23
Micardis (Renin-Angiotensin) B $13.49 $60.00 $62.65
Mirtazapine (Anti-depressants) G $0.00 $22.71 NA
Nadolol (Beta Blockers) G $0.00 $13.35 $16.48
Namenda (Anti-dementia Agents) B $15.00 $100.30 NA
Nardil (Anti-depressants) B $12.27 $49.30 NA
Nefazodone (Anti-depressants) G $0.00 $25.41 $39.66
Neurontin (Other Commonly Used Drugs) B $30.08 $90.08 $151.42
Nexium (Proton Pump Inhibitors) B* $17.00 $62.86 $164.52
Niaspan (ER) (Cholesterol Agents) B $12.19 $50.00 $52.78
Nicardipine (Calcium Channel Blockers) G $0.00 $15.17 $39.89
Nifedipine (Calcium Channel Blockers) G $4.00 $20.24 $64.35
Nimotop (Calcium Channel Blockers) B $17.00 $1,800.47 $2,169.76
Nortriptyline (Anti-depressants) G $0.00 $20.99 NA
Norvasc (Calcium Channel Blockers) B* $15.00 $62.33 $62.44
Omeprazole (Proton Pump Inhibitors) G $0.00 $40.00 $135.83
Pamidronate (Hormonal Agents) G $4.00 $224.42 $876.84
Parnate (Anti-depressants) B $15.00 $76.86 NA
Paroxetine (Anti-depressants) G $0.00 $20.58 NA
Paxil CR (Anti-depressants) B $17.00 $80.34 $100.99
Pindolol (Beta Blockers) G $0.00 $15.63 NA
Plavix (Other Commonly Used Drugs) B* $15.00 $66.00 $154.93
Potassium Chloride (Other Commonly Used Drugs) G* $0.00 $11.39 NA
Prandin (Oral Hypoglycemics) B $15.00 $66.00 $100.38
Pravachol (Cholesterol Agents) B $27.00 $99.46 $142.09
Precose (Oral Hypoglycemics) B $15.00 $66.00 $68.09
Prednisone (Other Commonly Used Drugs) G $0.00 $6.80 NA
Prevacid DR (Proton Pump Inhibitors) B $17.00 $93.11 $165.13
Table A4: Minimum and Maximum Costs for 152 Sample Drugs 
(both Covered and Uncovered) (continued)
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Drug Name (Drug Group)
Brand/
Generic
Minimum 
Cost 
Sharing 
for Drug 
if Covered
Maximum 
Cost 
Sharing 
for Drug 
if Covered
Maximum 
Cost for 
Drug 
if Not 
Covered
Prilosec CR (Proton Pump Inhibitors) B $25.00 $103.86 $208.69
Propoxyphene-N/Acetaminophen (Other Commonly Used Drugs) G $0.00 $6.95 $19.52
Propranolol HCL (Beta Blockers) G $0.00 $10.00 NA
Protonix (Proton Pump Inhibitors) B $20.00 $86.44 $129.86
Prozac Weekly (Anti-depressants) B $22.77 $82.77 $101.51
Quinapril (Renin-Angiotensin) G $0.00 $14.32 $61.74
Razadyne (Anti-dementia Agents) B $17.00 $66.81 $156.31
Remicade (TNF Inhibitors) B $20.00 $1,177.24 $1,385.22
Skelid (Hormonal Agents) B $40.00 $402.55 $608.92
Sotalol HCL (Beta Blockers) G $0.00 $21.85 $58.75
Spironolactone (Renin-Angiotensin) G $0.00 $10.74 NA
Starlix (Oral Hypoglycemics) B $15.00 $66.00 $122.51
Sular CR (Calcium Channel Blockers) B $12.10 $51.15 $51.40
Surmontil (Anti-depressants) B $20.00 $86.35 NA
Synthroid (Other Commonly Used Drugs) B $3.74 $18.81 $18.81
Teveten (Renin-Angiotensin) B $12.97 $52.14 $53.89
Timolol Maleate (Beta Blockers) G $0.00 $9.63 $9.63
Tolazamide (Oral Hypoglycemics) G $0.00 $11.77 $18.09
Tolbutamide (Oral Hypoglycemics) G $0.00 $9.68 $10.26
Toprol XL (Beta Blockers) B* $6.37 $26.25 NA
Trazodone (Anti-depressants) G $0.00 $10.00 NA
Triamterene/HCTZ (Other Commonly Used Drugs) G $0.00 $9.00 NA
Tricor (Cholesterol Agents) B $17.00 $65.30 $111.60
Verapamil (Calcium Channel Blockers) G $0.00 $12.63 NA
Vivactil (Anti-depressants) B $20.00 $91.88 $142.50
Warfarin (Other Commonly Used Drugs) G* $0.00 $10.00 NA
Welchol (Cholesterol Agents) B $20.00 $100.54 $178.40
Wellbutrin XL (Anti-depressants) B $17.00 $65.30 $132.90
Zetia (Cholesterol Agents) B $17.00 $66.00 $74.64
Zithromax (Other Commonly Used Drugs) B $4.92 $33.14 $33.14
Zithromax Z-Pak (Other Commonly Used Drugs) B $2.21 $11.31 $11.12
Zocor (Cholesterol Agents) B* $15.00 $93.35 $153.12
Zoloft (Anti-depressants) B* $17.00 $66.00 NA
Zometa (Hormonal Agents) B $20.00 $274.87 $1,003.39
NOTE: * indicates top 10 brand-name/generic drug. 
NA (not applicable) - maximum cost for drug if not covered is not applicable when drug is covered by all plans.
SOURCE: Authors' analysis of drug coverage in stand-alone PDPs offered by 14 national and near-national organizations; 
data from Medicare.gov.
Table A4: Minimum and Maximum Costs for 152 Sample Drugs 
(both Covered and Uncovered) (continued)
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APPENDIX B: COVERAGE AND COST OF SAMPLE DRUGS  
IN SELECTED DRUG GROUPS 
 
The ultimate cost paid by a beneficiary for a drug brings together the drug’s status on or off 
the formulary as well as the cost sharing assigned to the drug if it is on formulary.  From 
the perspective of enrollees, the tier to which a drug is assigned is not as important as how 
tier assignment affects cost sharing, since for many beneficiaries, whether a drug is on the 
formulary is considerably less important than their out-of-pocket cost.  To illustrate, an off-
formulary drug with a total monthly cost of $12 will cost an enrollee less than a similar on-
formulary drug with a total monthly cost of $80, but where the enrollee copayment for that 
drug is $20.  Cost calculations for enrollees get more complicated, however, when factoring 
in the coverage gap and the rules for what counts as “true out-of-pocket costs” (or TrOOP).  
In the case of the example above, when the beneficiary reaches the coverage gap, the 
relative savings is even greater for the off-formulary drug.  But an important consideration 
for off-formulary drug purchases is that, whether before or during the doughnut hole, the 
$12 monthly cost of the off-formulary drug would not be considered “true out-of-pocket 
costs” that would count toward the $3,600 threshold for catastrophic coverage.  
 
In the analysis presented in this appendix, we look at total costs to beneficiaries in the 
initial coverage period based on their taking one drug.  Users of multiple drugs or those 
whose costs place them beyond the initial coverage period may have different costs because 
of the effect of the coverage gap or the catastrophic benefit.  The cost identified for a drug 
is either the cost sharing in the initial coverage period if a drug is on the plan’s formulary or 
the total cost charged by that plan for an off-formulary drug based on the cost displayed on 
the Medicare Plan Finder website.   
 
For simplicity, we focus in this section on the costs for one plan for each of the 14 national 
or near-national organizations in this study.  Each is either the lowest-premium plan or the 
only plan offered by that particular organization.  As described elsewhere, some of the 
higher-premium plans offered by these organizations have more extensive formularies; this 
analysis does not address those variations.  Instead, it focuses on the less expensive plans 
that are likely to be more 
attractive to many enrollees.  
Table B1 shows the copayment 
or coinsurance rules that are 
applied by each of the 14 plans 
that are the focus of the 
analysis in this appendix.  
We focus on several drug 
groups that include some of the 
most commonly prescribed 
drugs.  These are generally at 
the smaller class (second) level 
or the key drug (third) level of 
the USP classification system.  
We also report, in less detail, on 
some of the related drug groups 
that complete the drug 
categories and classes used 
throughout the main report. 
Table B1: Cost Sharing by Formulary Tier, by Plan
Tier 1 Tier 2 Tier 3 Specialty
Aetna Essentials $5 $25 None None
Caremark Silverscript $9 25% None 25%
Cigna Value $4 $20 $40 None
Coventry AdvantraRx Value $10 $42 None None
Humana Standard 25% None None None
Medco $4 $17 75% 25%
MemberHealth CCRX Basic $0 25% 45% None
Pacificare Saver $7.50 $22 $52.70 33%
Prescription Pathway Bronze 25% None None None
Sterling $10 $25 50% 25%
Unicare Medicare Rx Rewards $5 $25 None 25%
United American $9 $30 $60 33%
United Healthcare AARP $5 $28 $55 25%
Wellcare Signature $0 $66 None 31%
NOTE:  For plans with small variations in cost sharing by region, this table 
indicates the value for Region 5, which is the region used as our data 
collection point in this study. Plans included represent the lowest-
premium (or only) plan for each of the 14 organizations in the study.
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Drugs Used to Treat Ulcers 
 
Proton Pump Inhibitors 
 
Proton pump inhibitors (PPIs), used to treat ulcers or GERD, includes five relatively 
expensive drugs (generally priced at over $100 for one month’s supply), one of which 
(omeprazole) is available in generic form and in fact is available over the counter at lower 
doses.  Our drug sample includes these five products as well as the brand version of 
omeprazole.  In the USP classification scheme, PPIs constitute one drug class in the larger 
category of gastrointestinal agents; as such, the statutory requirement requires that plans 
cover at least two PPIs.  For the set of drugs in this class, there seems to be little evidence 
for the clinical superiority of one product over another.  Thus, it is a class where plans have 
a fairly high incentive to select a preferred product and where beneficiaries should be able 
to switch products with relatively little difficulty. 
 
Beneficiaries with a preference (or a current prescription) for one particular product will see 
large differences across these 14 plans.  A Nexium user will save $148 by picking Medco 
over Wellcare Signature, while a Protonix user will save $104 by picking Aetna Essentials 
over Medco and another $5 by picking Cigna Value.  Or these beneficiaries can ask their 
doctors to change their prescriptions and achieve similar savings within a given plan. 
 
All but one of these 14 plans meet the two-drug requirement, and it could be that Coventry 
AdvantraRx Value (which covers only Protonix) uses a different classification system or 
received an exception from CMS.  But otherwise, plans range from covering just two to all 
six products on formulary (all five of the unique chemicals).  Plans seem to have adopted 
different strategies around the use of omeprazole – with 11 plans giving the generic version 
a low Tier 1 copayment but three plans denying it formulary status perhaps because of its 
availability over the counter.  Mostly, the plans discouraged use of the brand version of 
omeprazole (Prilosec), with only 5 of 14 plans putting it on formulary.  Overall, Nexium, 
Prevacid, and the generic omeprazole were mostly likely, among the drugs in this class, to 
be on formulary.  By contrast, Aciphex was only on formulary for three of 14 plans. 
Table B2: Coverage and Cost of Proton Pump Inhibitors, by Plan
Aciphex Nexium
Omepra-
zole* Prevacid
Prilosec 
CR Protonix
Aetna Essentials $130 $132 $66 $25 $176 $25
Caremark Silverscript $144 $33 $9 $33 $44 $129
Cigna Value $40 $40 $135 $40 $206 $20
Coventry AdvantraRx Value $130 $132 $136 $163 $206 $42
Humana Standard $32 $33 $10 $33 $44 $26
Medco $145 $17 $4 $17 $71 $129
MemberHealth CCRX Basic $147 $33 $0 $165 $209 $27
Pacificare Saver $129 $22 $8 $132 $207 $22
Prescription Pathway Bronze $132 $33 $8 $34 $178 $107
Sterling $145 $25 $10 $25 $25 $130
Unicare Medicare Rx Rewards $130 $132 $5 $25 $176 $25
United AARP $55 $28 $5 $55 $207 $28
United American $145 $30 $9 $30 $60 $130
Wellcare Signature $143 $165 $0 $162 $205 $66
NOTE: Shaded cell indicates off-formulary drug for specific plan. * indicates generic drug.
SOURCE: Authors' analysis of drug coverage in stand-alone PDPs offered by 14 national and near-national 
organizations.  Plans included represent the lowest-premium (or only) plan for each of the 14 organizations in the 
study.  Data from Medicare.gov. 
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Drugs Used to Treat High Cholesterol 
 
Statins 
 
The statins are considered a key drug type in the USP classification system and grouped 
with other treatments for high cholesterol to form a drug class.  There are separate 
chemical entities in this group, and we included three forms of lovastatin (the generic 
version and two brand alternatives – Mevacor, the original brand version, and Altoprev).  
Other than lovastatin, the drugs in this class are currently available only as brand products.  
As a result, they are typically priced between $60 and $140. 
 
Two of the 14 plans have included all of the statins on their formularies, and four others 
include all except the brand version of lovastatin (Mevacor).  As a result of tier differences, 
beneficiaries can still achieve savings by choosing the generic lovastatin over the various 
brand products or by choosing a preferred brand drug over a non-preferred drug.  By 
contrast, six plans have only three or fewer products on formulary, typically Lipitor, Zocor, 
and the generic lovastatin.  In most of these cases, the beneficiary can save over $100 by 
switching to a preferred brand product – or even more by switching to generic lovastatin.   
 
The two most popular drugs in this group, Lipitor and Zocor, receive similar treatment.  
Zocor is left off two formularies, compared to one for Lipitor, and Lipitor is available at a 
lower price than Zocor slightly more often, but nearly half the plans provide preferred status 
to both.  Both of these popular drugs generally do better on the formularies than less 
commonly prescribed competitors such as Crestor, Lescol, or Pravachol – which are omitted 
from about half of the formularies.  All but one of the plans offer the lowest cost sharing to 
beneficiaries that select generic lovastatin.  But about half the plans make at least one of 
the branded versions of lovastatin (Altoprev or Mevacor) available at relatively low prices as 
well.  Coventry’s AdvantraRx Value is the exception here, leaving generic lovastatin off its 
formulary but covering the branded version, Altoprev, at the generic tier rate. 
 
 
 
Table B3: Coverage and Cost of Dyslipidemics (Statins), by Plan
Altoprev Crestor Lescol Lipitor
Lova-
statin* Mevacor
Prava-
chol Zocor
Aetna Essentials $93 $81 $58 $25 $5 $69 $132 $25
Caremark Silverscript $100 $20 $14 $18 $9 $88 $140 $153
Cigna Value $40 $40 $20 $40 $4 $24 $40 $20
Coventry AdvantraRx Value $10 $81 $58 $74 $123 $89 $132 $42
Humana Standard $23 $20 $14 $18 $8 $17 $33 $33
Medco $17 $17 $43 $17 $4 $89 $99 $17
MemberHealth CCRX Basic $102 $101 $72 $19 $0 $91 $142 $34
Pacificare Saver $100 $99 $70 $53 $8 $89 $140 $22
Prescription Pathway Bronze $94 $20 $58 $18 $12 $89 $34 $135
Sterling $47 $25 $25 $25 $10 $89 $66 $67
Unicare Medicare Rx Rewards $93 $81 $58 $25 $5 $17 $132 $25
United AARP $55 $55 $55 $28 $5 $89 $55 $28
United American $30 $30 $58 $30 $9 $89 $60 $30
Wellcare Signature $99 $97 $69 $66 $0 $88 $139 $66
NOTE: Shaded cell indicates off-formulary drug for specific plan. * indicates generic drug.
SOURCE: Authors' analysis of drug coverage in stand-alone PDPs offered by 14 national and near-national organizations.  
Plans included represent the lowest-premium (or only) plan for each of the 14 organizations in the study.  Data from 
Medicare.gov. 
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Other Cholesterol Medications 
 
Although we are not presenting a complete analysis of the other four key drug types in the 
USP classification system for treating high cholesterol, there are some notable results.  
Among the three bile acid sequestrants, plans cover between one and three of the products.  
The most commonly covered product is the generic cholestyramine, which is on 11 of 14 
formularies.  The two competing products are covered on only about half the formularies, 
resulting in considerable price variation.  There are two products in the fibrates key drug 
type.  All plans have chosen to cover the generic gemfibrozil, while 11 plans also cover 
Tricor.  Because Tricor is covered as a brand drug, it is also at least twice as expensive and 
sometimes far higher.  Zetia is the only product in the key drug type known as lipid 
absorption inhibitors and thus should always be covered according to CMS guidelines.  Two 
plans do not cover this drug, perhaps having gotten permission to exclude it.  The last key 
drug has only the drug Niaspan, which will cease to be covered, based on a recent CMS 
ruling, because it is a vitamin. 
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Drugs Used to Treat Depression 
 
Antidepressants: SSRIs 
 
SSRIs are the most commonly prescribed antidepressants, but they also tend to be the 
newest and most expensive drugs in the overall category of drugs.  According to CMS 
guidelines, plans must cover most or all drugs in this entire category.  But the guidelines 
make it clear that plans are not required to cover the extended-release drug variants (Paxil 
CR or Prozac Weekly), and the guidelines explicitly allowed plans to choose between 
citalopram and Lexapro.  Four drugs are available in generic form; only Lexapro and Zoloft 
lack a generic alternative. 
 
Nearly all of these plans chose to take advantage of the exceptions to the CMS “all or 
substantially all” guideline.  Eleven plans require beneficiaries to pay full price for Prozac 
Weekly, and seven do the same for Paxil CR.  Five plans chose not to cover Lexapro in favor 
of covering citalopram.37  With one exception, all these plans provide coverage in the lowest 
tier for the generic antidepressants, but the cost sharing is generally higher for Humana 
Standard and Prescription Pathway Bronze, since they employ a standard benefit with 25 
percent coinsurance in all tiers.  These two plans generally have a smaller cost-sharing 
differential between the brand and generic alternatives.  In addition, two plans place Zoloft 
(the most prescribed drug in this group) in the non-preferred tier thus creating a significant 
financial incentive against its use.  Beneficiaries who prefer to stay with Zoloft can cut their 
costs at least in half by choosing most of the plans that cover it on the preferred tier. 
 
                                                 
37 On this chart, Humana Standard is shown not covering citalopram.  Since the time of our data collection, they 
have indicated that this drug is on formulary.  The resulting price, however, is about the same. 
Table B4: Coverage and Cost of Antidepressants (SSRIs), by Plan
Citalo-
pram*
Fluoxe-
tine*
Fluvoxa-
mine* 
Lexa-
pro
Paroxe-
tine*
Paxil 
CR
Prozac 
Weekly Zoloft
Aetna Essentials $5 $5 $5 $68 $5 $86 $92 $25
Caremark Silverscript $9 $9 $9 $17 $9 $98 $99 $20
Cigna Value $4 $4 $4 $40 $4 $40 $40 $40
Coventry AdvantraRx Value $9 $5 $10 $42 $10 $82 $91 $42
Humana Standard $12 $2 $15 $17 $14 $20 $23 $20
Medco $4 $4 $4 $85 $4 $17 $100 $17
MemberHealth CCRX Basic $0 $0 $0 $87 $0 $101 $102 $20
Pacificare Saver $8 $8 $53 $53 $8 $81 $100 $53
Prescription Pathway Bronze $6 $1 $9 $17 $13 $99 $100 $20
Sterling $10 $10 $10 $25 $10 $43 $99 $25
Unicare Medicare Rx Rewards $5 $5 $5 $85 $5 $86 $91 $25
United AARP $5 $5 $5 $28 $5 $55 $55 $28
United American $9 $9 $9 $85 $9 $30 $100 $30
Wellcare Signature $0 $0 $0 $66 $0 $66 $98 $66
NOTE: Shaded cell indicates off-formulary drug for specific plan. * indicates generic drug.
SOURCE: Authors' analysis of drug coverage in stand-alone PDPs offered by 14 national and near-national organizations.  
Plans included represent the lowest-premium (or only) plan for each of the 14 organizations in the study.  Data from 
Medicare.gov. 
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Other Antidepressants 
 
In addition to the SSRIs, the antidepressant category includes two other classes and two 
other key drug types in the reuptake inhibitors class that includes SSRIs.  According to CMS 
guidelines, plans should cover all of these products.  In the additional two key drug types of 
the reuptake inhibitors class, the tricyclics are nearly universally covered – other than one 
drug that is omitted by one plan.  Most of these drugs are generics, and are covered with 
modest cost sharing, although the different plan designs and drug prices mean that cost 
sharing ranges from $0 to $28.  The two brand products amount this group are covered at 
cost sharing levels from $20 to $92.  For the SNRIs, two products are skipped on at least 
two plan formularies each.  All plans cover the third (Effexor) in at least one of its two 
formulations, and most cover both formulations in our study sample.  In part because of the 
formulary omissions, the cost of these drugs varies substantially depending on which plan a 
beneficiary selects. 
 
There are two other drug classes among the antidepressants.  The MAO inhibitors include 
just two brand-name products.  While all plans cover these two drugs and price them 
similarly to each other, their cost in some plans is about four times as high as in other 
plans.  By contrast, not all plans cover the four unique chemical products in the other 
antidepressants class.  One of the drugs is omitted by two formularies.  Our study sample 
contains three versions of the drug bupropion.  All plans cover at least one of the generic 
versions, and all but two plans cover the brand version (Wellbutrin XL), albeit at higher 
cost-sharing levels.  This is consistent with the guidelines that do not require that plans 
cover special versions of a drug, such as extended-release versions taken just one time a 
day. 
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Drugs Used to Treat Hypertension 
 
Angiotensin Receptor Blockers 
 
There are seven angiotensin receptor blockers (ARBs) in this key drug type that is part of 
the rennin-angiotensin aldosterone system inhibitors class.  As a result, CMS guidelines 
require that at least one be covered.  All are available only as brand products, and there are 
no variations among the products we analyzed.  The actual cost of a monthly supply of 
drugs in this group are more modest than some of the other brand products discussed 
above, ranging from about $45 to $75. 
 
Plans handled this set of drugs quite differently.  Six plans placed only two of the seven 
drugs on formulary, meaning that beneficiaries using the off-formulary products will pay 
double to triple the price to obtain these drugs.  Three plans cover all seven drugs, but two 
divide the drugs between preferred and non-preferred tiers, resulting in a doubling of the 
cost-sharing amount.  In contrast, under Humana Standard, with its standard benefit, all 
seven drugs have roughly the same cost sharing.  Other plans fall somewhere in between 
these extremes.  
 
Certain drugs were more likely to be given preferred placement on plan formularies.  
Diovan, the most commonly prescribed product in this group, has preferred status on 13 of 
14 formularies, and Cozaar is covered on 11 of 14 formularies (but not always with 
preferred status).   By contrast, Teveten is off formulary in 11 plans and covered only on a 
non-preferred tier by two other plans.  Most of the other products in this group are covered 
by about half the plans, but are generally more likely to be on the non-preferred tier when 
covered. 
 
Table B5: Coverage and Cost of Renin-angiotensin-aldosterone System Inhibitors (ARBs),
Atacand Avapro Benicar Cozaar Diovan Micardis Teveten
Aetna Essentials $62 $47 $47 $25 $25 $54 $52
Caremark Silverscript $74 $12 $13 $12 $12 $60 $51
Cigna Value $40 $40 $40 $40 $20 $20 $40
Coventry AdvantraRx Value $62 $42 $46 $49 $50 $42 $52
Humana Standard $15 $12 $12 $12 $12 $13 $13
Medco $17 $17 $54 $17 $17 $17 $52
MemberHealth CCRX Basic $76 $65 $56 $13 $16 $63 $54
Pacificare Saver $74 $63 $22 $69 $22 $61 $52
Prescription Pathway Bronze $16 $47 $47 $49 $13 $55 $53
Sterling $31 $25 $23 $25 $25 $27 $52
Unicare Medicare Rx Rewards $62 $47 $46 $25 $25 $54 $52
United AARP $55 $28 $28 $48 $28 $55 $52
United American $30 $30 $54 $30 $30 $30 $52
Wellcare Signature $73 $62 $45 $66 $63 $53 $51
NOTE: Shaded cell indicates off-formulary drug for specific plan. 
SOURCE: Authors' analysis of drug coverage in stand-alone PDPs offered by 14 national and near-national organizations.  
Plans included represent the lowest-premium (or only) plan for each of the 14 organizations in the study.  Data from 
Medicare.gov. 
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ACE Inhibitors 
 
Of the nine drugs in this key drug type in the renin-angiotensin aldosterone system 
inhibitors class, the six generics are covered by at least 13 of the 14 plans and at cost-
sharing amounts of $10 or less.  The brand options in this group are much less likely to be 
covered and are more expensive when they are covered. 
 
Cardioselective Beta Blockers 
 
Most of the drugs in the cardioselective beta blockers key drug type in the larger class of 
beta blockers are available in generic form, and most are inexpensive drugs.  The one 
exception is Toprol XL, a commonly prescribed extended-release version of Metoprolol.  As a 
key drug type, the CMS guidelines require that at least one drug be covered.  Several of the 
drugs in this group are among the most commonly prescribed drugs used by Medicare 
beneficiaries. 
 
Because most of these drugs are generics, it is not surprising that four of the six drugs in 
this group are covered by all plans – and at similar cost to the beneficiary.  Toprol XL, the 
only brand in this group and one of the top 10 most commonly prescribed brand drugs, is 
typically several dollars more expensive than the others.  But given its relatively low list 
price, users often pay close to full price for this drug.  Four plans chose to leave one or two 
of the products in this group off their formularies.  Enrollees in these plans who chose to 
remain with these products would pay considerably more as a result.  The standard benefit 
offered by Humana Standard and Prescription Pathway Bronze means that the cost of these 
beta blockers rises and falls with the underlying costs of the drug.  Thus, users of Toprol XL, 
Metoprolol, or Atenolol would save by joining these plans, but users of Acebutolol would 
face somewhat higher costs. 
 
Table B6: Coverage and Cost of Cardioselective Beta Blockers, by Plan
Acebu-
tolol* Atenolol*
Betax-
olol*
Biso-
prolol*
Meto-
prolol* Toprol XL
Aetna Essentials $5 $4 $5 $5 $4 $25
Caremark Silverscript $62 $3 $68 $9 $5 $6
Cigna Value $4 $4 $4 $4 $4 $20
Coventry AdvantraRx Value $10 $4 $10 $10 $5 $26
Humana Standard $12 $1 $7 $7 $1 $6
Medco $4 $4 $4 $4 $4 $17
MemberHealth CCRX Basic $0 $0 $68 $0 $0 $7
Pacificare Saver $25 $6 $30 $8 $5 $22
Prescription Pathway Bronze $6 $1 $8 $8 $1 $7
Sterling $62 $3 $68 $10 $5 $25
Unicare Medicare Rx Rewards $5 $4 $5 $5 $5 $25
United AARP $5 $4 $5 $5 $5 $25
United American $9 $5 $9 $9 $6 $26
Wellcare Signature $0 $0 $0 $0 $0 $24
NOTE: Shaded cell indicates off-formulary drug for specific plan. * indicates generic drug.
SOURCE: Authors' analysis of drug coverage in stand-alone PDPs offered by 14 national and near-national 
organizations.  Plans included represent the lowest-premium (or only) plan for each of the 14 organizations in 
the study.  Data from Medicare.gov. 
 45
Nonselective Beta Blockers 
 
The pattern for nonselective beta blockers, the other large key drug type of beta blockers, is 
similar to the cardioselective beta blockers, but with slightly more variation.  The six 
generics in this group are covered on between 11 and 14 formularies.  The one brand drug 
in the group is covered by only three plans.  Only one plan omits as many as three of the 
seven drugs in this group. 
 
Calcium Channel Blockers 
 
The calcium channel blockers drug class of hypertension medications has two key drug 
types:  dihydropyridines (with seven drugs) and non-dihydropyridines (with two drugs).  
Coverage in this class is quite mixed.  Plans cover between two and seven of the seven 
dihydropyridines, while all plans cover the two non-dihydropyridines.  One drug (Dynacirc) 
in the first key drug type is rarely covered (just two plans), while two of the seven, 
including the commonly prescribed Norvasc, are covered by 13 of 14 plans.  Typically 
coverage is broadest among the generics in the group.  Among the rest, Nimotop is the 
most expensive drug in our study sample (list price of over $2,000).  It is uncovered by 
seven plans and covered on a specialty tier by three other plans, but on a tier with a 
modest copayment by four others.  The result is that enrollees’ out-of-pocket costs vary 
widely for this drug, which is used in only rare circumstances. 
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Drugs Used to Treat Diabetes 
 
Oral Hypoglycemics 
 
This drug class of oral hypoglycemics contains five separate key drug types.  Four of these 
subgroups (shown below in Table B7) contain only one or two drugs, while the 
sulfonylureas group (shown in Table B8) has six drugs (two alternate forms in the latter 
group are excluded from this analysis).  Most of the drugs in this class are relatively 
inexpensive, but drugs in two of the key drug types are brand-name drugs that come at a 
higher price tag. 
 
All 14 plans meet the CMS guidelines of covering at least one drug in each key drug type.  
The sole drug among the biguanides (metformin) is a commonly prescribed drug available 
as a generic and is always priced at $10 or below.  The alpha glucosidase inhibitors, the 
meglitinides, and the thiazolidinediones each have two brand-name drugs.  In the first two 
groups, many plans chose to cover one of the two alternatives, but seemed to always put 
one in the preferred tier (for plans making such distinctions).  Both drugs in the 
thiazolidinediones are covered by most of the plans, and many plans have placed both in 
the preferred tier.  There are clear favorites in each class:  Precose over Glyset, Prandin 
over Starlix, and Avandia over Actos.   
 
Table B7: Coverage and Cost of Oral Hypoglycemics , by Plan
Biguanides
Glyset Precose Metformin* Prandin Starlix Actos Avandia
Aetna Essentials $25 $68 $5 $25 $25 $25 $25
Caremark Silverscript $72 $17 $9 $25 $122 $40 $22
Cigna Value $40 $20 $4 $20 $40 $20 $20
Coventry AdvantraRx Value $72 $42 $10 $42 $104 $42 $42
Humana Standard $15 $17 $3 $25 $26 $40 $20
Medco $46 $17 $4 $17 $17 $17 $17
MemberHealth CCRX Basic $28 $17 $0 $26 $26 $41 $23
Pacificare Saver $72 $53 $8 $53 $123 $161 $53
Prescription Pathway Bronze $16 $17 $3 $25 $26 $41 $21
Sterling $72 $25 $10 $25 $122 $25 $25
Unicare Medicare Rx Rewards $62 $25 $5 $100 $25 $25 $25
United AARP $55 $28 $5 $55 $28 $28 $28
United American $60 $30 $9 $30 $30 $30 $30
Wellcare Signature $71 $66 $0 $66 $66 $251 $66
Alpha Glucosidase 
Inhibitors Meglitinides
Thiazolidined-
iones
NOTE: Shaded cell indicates off-formulary drug for specific plan. * indicates generic drug.
SOURCE: Authors' analysis of drug coverage in stand-alone PDPs offered by 14 national and near-national organizations.  
Plans included represent the lowest-premium (or only) plan for each of the 14 organizations in the study.  Data from 
Medicare.gov. 
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In the larger sulfonylureas group, two commonly prescribed products (glipizide and 
glyburide) are covered by all plans.38  Fewer plans (from seven to nine) cover the other four 
products in this group.  Only one is a brand-name drug and thus is placed on a higher cost-
sharing tier.  Those enrollees who are prescribed a product in this group other than the two 
most common ones may have to shop more carefully among plans.  Three plans cover just 
the two common products, while three plans cover all six.   
 
                                                 
38 Omitted from the table are the extended-release version of glipizide and the micronized version of glyburide.  
The one plan shown not to cover glipizide covers the extended-release version at a zero copay.  All but two plans 
cover the micronized version of glyburide at the same or similar copayment. 
Table B8: Coverage and Cost of Oral Hypoglycemics (Sulfonylureas), by Plan
Amaryl
Chlorpro-
pamide* Glipizide*
Glybu-
ride*
Tolaza-
mide*
Tolbuta-
mide*
Aetna Essentials $37 $11 $3 $5 $5 $5
Caremark Silverscript $46 $23 $4 $8 $18 $10
Cigna Value $20 $4 $3 $4 $4 $4
Coventry AdvantraRx Value $37 $10 $4 $8 $10 $6
Humana Standard $9 $4 $1 $2 $5 $2
Medco $17 $23 $4 $4 $4 $4
MemberHealth CCRX Basic $12 $0 $0 $0 $0 $10
Pacificare Saver $37 $23 $5 $8 $18 $10
Prescription Pathway Bronze $46 $4 $1 $3 $4 $2
Sterling $18 $23 $4 $8 $18 $10
Unicare Medicare Rx Rewards $46 $23 $4 $5 $18 $10
United AARP $28 $5 $4 $5 $5 $5
United American $30 $23 $4 $8 $9 $9
Wellcare Signature $35 $0 $11 $0 $17 $10
NOTE: Shaded cell indicates off-formulary drug for specific plan. * indicates generic drug.
SOURCE: Authors' analysis of drug coverage in stand-alone PDPs offered by 14 national and near-national 
organizations.  Plans included represent the lowest-premium (or only) plan for each of the 14 organizations in 
the study.  Data from Medicare.gov. 
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Drugs Used to Treat Dementia, Including Alzheimer’s Disease 
 
Drugs in this category are used to treat dementia, including Alzheimer;s disease.  All drugs 
in this category are brand products, except for Ergoloid Mesylates.  There are three classes 
within this category, with Namenda and Erologoid Mesylates each forming their own group.  
Thus, the formulary guidelines require that plans cover each of those drugs, plus two of the 
other four drugs.  Several of the drugs in this group are high-priced drugs. 
 
In this drug category, beneficiaries face a wide range in cost sharing depending on the drug 
they take and the plan they select.  All plans chose to cover Aricept and Namenda (and all 
but one covers Exelon) – but even here tier placement results in swings in cost sharing that 
range from 2:1 to 5:1.  The cheapest drugs overall are Aricept (the most commonly 
prescribed in this group) and, where available, Ergoloid Mesylates (the only generic in the 
group).  The omission from some formularies of drugs such as Cognex or Razadyne means 
that the range of costs for those can be nine times higher in some plans compared to 
others.  Ergoloid Mesylates should be covered by all plans as a distinct key drug type, but is 
off formulary for seven of 14 plans.  Because it is an expensive generic drug it would cost 
the beneficiary only $4 or $5 when covered, but cost over $100 in most of the plans where 
it is off formulary.  Only one plan (United AARP) covers all six of these drugs, while three 
plans limit coverage to just three products. 
 
Table B9: Coverage and Cost of Anti-Dementia Drugs, by Plan
Other 
Agents
Glutamate 
Pathway 
Modifiers
Aricept Cognex Exelon Razadyne
Ergoloid 
Mesylates* Namenda
Aetna Essentials $25 $300 $25 $148 $5 $25
Caremark Silverscript $35 $352 $40 $147 $103 $33
Cigna Value $20 $40 $40 $156 $4 $20
Coventry AdvantraRx Value $42 $299 $158 $42 $10 $42
Humana Standard $35 $75 $40 $37 $80 $33
Medco $17 $352 $17 $17 $103 $100
MemberHealth CCRX Basic $36 $354 $71 $37 $104 $34
Pacificare Saver $53 $352 $53 $156 $103 $22
Prescription Pathway Bronze $35 $352 $40 $156 $23 $34
Sterling $25 $352 $25 $148 $103 $25
Unicare Medicare Rx Rewards $25 $299 $25 $25 $5 $25
United AARP $28 $55 $55 $28 $5 $28
United American $30 $352 $30 $30 $103 $60
Wellcare Signature $66 $351 $66 $155 $0 $66
Cholinesterase Inhibitors
NOTE: Shaded cell indicates off-formulary drug for specific plan. * indicates generic drug.
SOURCE: Authors' analysis of drug coverage in stand-alone PDPs offered by 14 national and near-national 
organizations.  Plans included represent the lowest-premium (or only) plan for each of the 14 organizations 
in the study.  Data from Medicare.gov. 
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Hormonal Agents (Parathyroid/Metabolic Bone Disease) 
 
The class of hormonal agents for parathyroid and metabolic bone disease is something of a 
mixed bag clinically.  There are two key drug types in our study sample:  biphosphonates 
and calcium regulating hormones.  While two drugs in the biphosphonates group (Actonel 
and Fosamax) are commonly prescribed drugs for osteoporosis, the others 
(Aredia/pamidronate, Didronel, Skelid, and Zometa) are treatments for cancer or Paget’s 
Disease.39  The two calcium regulating hormones can be used for osteoporosis but may have 
other clinical uses.  Most of these drugs are expensive; in fact, several have prices in the 
range of $600 to $1,000.  
 
All plans meet the CMS guidelines of covering at least one drug in each of the key drug 
types, but the coverage is especially uneven among the products in this class.  Most plans 
cover the two most common treatments for osteoporosis (Actonel and Fosamax) and 
generally do so in the preferred brand tier.  The treatments in the calcium regulating 
hormones key drug type are also covered by most plans.  But Forteo is often on the 
specialty tier and comes at a considerably higher price tag than the others. 
 
The remaining five drugs in this class are covered by fewer than half the plans.  These 
expensive drugs treat less common conditions, and enrollees who take them have only a 
few plan options available if they want choice among these medications.  Because the base 
price for the cheapest drug in this set is nearly $200, and the others are at least $600, 
beneficiaries face high out-of-pocket costs.  But if they pick one of the two plans that cover 
all the drugs in this class, they will have both lower costs and more options. 
 
 
 
 
                                                 
39 Another treatment for osteoporosis, Boniva, was not included in the USP list of drugs and is thus not in the 
sample of drugs for this study. 
Table B10: Coverage and Cost of Hormonal agents (Biphosphonates) by Plan
Actonel Aredia Didronel Fosamax
Pami-
dronate* Skelid Zometa
Aetna Essentials $25 $842 $187 $25 $702 $537 $25
Caremark Silverscript $17 $841 $191 $17 $877 $606 $1,001
Cigna Value $40 $20 $20 $20 $4 $40 $20
Coventry AdvantraRx Value $70 $841 $187 $42 $877 $536 $860
Humana Standard $17 $179 $47 $17 $164 $134 $215
Medco $17 $842 $17 $17 $877 $403 $1,001
MemberHealth CCRX Basic $18 $844 $194 $18 $877 $609 $1,003
Pacificare Saver $22 $842 $192 $70 $877 $607 $1,001
Prescription Pathway Bronze $18 $842 $47 $18 $877 $607 $1,001
Sterling $25 $841 $192 $25 $876 $607 $1,001
Unicare Medicare Rx Rewards $25 $841 $187 $25 $877 $536 $1,001
United AARP $55 $841 $55 $28 $877 $607 $212
United American $30 $842 $30 $30 $877 $60 $1,001
Wellcare Signature $66 $840 $191 $66 $876 $606 $1,000
NOTE: Shaded cell indicates off-formulary drug for specific plan. * indicates generic drug.
SOURCE: Authors' analysis of drug coverage in stand-alone PDPs offered by 14 national and near-national 
organizations.  Plans included represent the lowest-premium (or only) plan for each of the 14 organizations in the 
study.  Data from Medicare.gov. 
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Forteo Miacalcin
Aetna Essentials $25 $86
Caremark Silverscript $151 $21
Cigna Value $20 $20
Coventry AdvantraRx Value $42 $42
Humana Standard $151 $21
Medco $17 $17
MemberHealth CCRX Basic $269 $22
Pacificare Saver $657 $53
Prescription Pathway Bronze $153 $22
Sterling $151 $25
Unicare Medicare Rx Rewards $151 $25
United AARP $149 $55
United American $30 $30
Wellcare Signature $656 $66
NOTE: Shaded cell indicates off-formulary drug for specific 
plan. 
SOURCE: Authors' analysis of drug coverage in stand-alone 
PDPs offered by 14 national and near-national 
organizations.  Plans included represent the lowest-premium 
(or only) plan for each of the 14 organizations in the study.  
Data from Medicare.gov. 
Table B11: Coverage and Cost of Hormonal 
Agents (Calcium Regulating Hormones), by 
Plan
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Drugs Used to Treat Rheumatoid Arthritis 
 
Tumor Necrosis Factor Inhibitors 
 
The three drugs in this group form a key drug type.  Beneficiaries with rheumatoid arthritis 
commonly use one of these drugs; all are injectable drugs that have high price tags.  
Remicade must be administered by a physician, and so is often covered under Medicare Part 
B, whereas Enbrel and Humira are self injectable, and so should normally be covered under 
Part D.  The full retail price of each of these drugs is in the range of $1,100 to $1,400 per 
month. 
 
Beneficiaries who use these drugs face the most dramatic cost differences of any of the 
drugs in this analysis.  Four plans place at least one of these drugs on a preferred tier (or 
sole brand tier) with flat copayments; in these cases, the cost to the beneficiary is between 
$17 and $42.  Two of these plans treat all three products similarly, while the others create 
large price differentials by placing these drugs on separate cost-sharing tiers.  For example, 
in the case of Medco’s PDP, the lower cost-sharing amount ($17 in this plan) applies to only 
one of the three drugs (Humira).  Medco placed Enbrel on Tier 3, with 75 percent 
coinsurance ($958), and left Remicade off its formulary ($1,385).  Of the eight plans with 
specialty tiers, six place these drugs on their specialty tier, meaning that enrollees would 
pay coinsurance in the range of $300 to $400.  Eight of the 14 plans give equal treatment 
to Enbrel and Humira, the two products that compete most directly because they can be 
injected by the patient, whereas the other plans give a more preferred status and 
substantially lower costs to one or the other, with savings that could range from a modest 
$30 to more than $1,000.  Remicade, which is often covered under Part B, is generally 
treated in comparable ways, and it is omitted from two formularies. 
 
Enbrel Humira Remicade
Aetna Essentials $25 $25 $25
Caremark Silverscript $319 $319 $294
Cigna Value $20 $20 $20
Coventry AdvantraRx Value $42 $1,277 $42
Humana Standard $319 $319 $294
Medco $958 $17 $1,385
MemberHealth CCRX Basic $569 $322 $525
Pacificare Saver $419 $1,338 $386
Prescription Pathway Bronze $323 $1,292 $298
Sterling $319 $319 $294
Unicare Medicare Rx Rewards $319 $319 $294
United AARP $315 $315 $290
United American $60 $30 $1,385
Wellcare Signature $391 $391 $360
Table B12: Coverage and Cost of Tumor Necrosis Factor 
Inhibitors, by Plan
NOTE: Shaded cell indicates off-formulary drug for specific plan. 
SOURCE: Authors' analysis of drug coverage in stand-alone PDPs offered by 
14 national and near-national organizations.  Plans included represent the 
lowest-premium (or only) plan for each of the 14 organizations in the study.  
Data from Medicare.gov. 
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